U.S. patent application number 12/111013 was filed with the patent office on 2009-06-04 for detection and modulation of iaps and naip for the diagnosis and treatment of proliferative disease.
This patent application is currently assigned to AEGERA THERPEUTICS, INC.. Invention is credited to Stephen Baird, Robert G. Korneluk, Peter Liston, Alexander E. Mackenzie, Christine Pratt, Benjamin K. Tsang.
Application Number | 20090142334 12/111013 |
Document ID | / |
Family ID | 25179735 |
Filed Date | 2009-06-04 |
United States Patent
Application |
20090142334 |
Kind Code |
A1 |
Korneluk; Robert G. ; et
al. |
June 4, 2009 |
DETECTION AND MODULATION OF IAPs AND NAIP FOR THE DIAGNOSIS AND
TREATMENT OF PROLIFERATIVE DISEASE
Abstract
Disclosed are diagnostic and prognostic kits for the detection
and treatment of proliferative diseases such as ovarian cancer,
breast cancer, and lymphoma. Also disclosed are cancer therapeutics
utilizing IAP antisense nucleic acids, IAP fragments, and
antibodies which specifically bind IAP polypeptides.
Inventors: |
Korneluk; Robert G.;
(Ottawa, CA) ; Mackenzie; Alexander E.; (Ottawa,
CA) ; Liston; Peter; (Ottawa, CA) ; Baird;
Stephen; (Ottawa, CA) ; Tsang; Benjamin K.;
(Nepean, CA) ; Pratt; Christine; (Nepean,
CA) |
Correspondence
Address: |
LOWRIE, LANDO & ANASTASI, LLP
ONE MAIN STREET, SUITE 1100
CAMBRIDGE
MA
02142
US
|
Assignee: |
AEGERA THERPEUTICS, INC.
Verdun
CA
|
Family ID: |
25179735 |
Appl. No.: |
12/111013 |
Filed: |
April 28, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11522896 |
Sep 19, 2006 |
|
|
|
12111013 |
|
|
|
|
09974592 |
Oct 9, 2001 |
7087584 |
|
|
11522896 |
|
|
|
|
09617053 |
Jul 14, 2000 |
6300492 |
|
|
09974592 |
|
|
|
|
08800929 |
Feb 13, 1997 |
6133437 |
|
|
09617053 |
|
|
|
|
Current U.S.
Class: |
514/1.1 ;
514/44R |
Current CPC
Class: |
A61K 38/1709 20130101;
C12Q 2600/136 20130101; G01N 33/5011 20130101; A61P 35/00 20180101;
C12N 15/1135 20130101; A61K 48/00 20130101; C12N 2310/11 20130101;
C12N 15/113 20130101; C12Q 2600/106 20130101; A01K 2217/05
20130101; C12N 2799/022 20130101; G01N 33/57496 20130101; C12Q
1/6886 20130101; C07K 14/4703 20130101 |
Class at
Publication: |
424/130.1 ;
514/2; 514/44 |
International
Class: |
A61K 48/00 20060101
A61K048/00; A61K 38/02 20060101 A61K038/02; A61K 39/395 20060101
A61K039/395; A61P 35/00 20060101 A61P035/00; A61K 31/7088 20060101
A61K031/7088 |
Claims
1. A method for enhancing apoptosis in a cell from a mammal with a
proliferative disease, the method comprising: administering to the
cell a compound that inhibits the biological activity of an IAP
polypeptide, the compound being administered to the cell in an
amount sufficient to enhance apoptosis in the cell.
2. The method of claim 1, wherein the cell is proliferating in the
proliferative disease.
3. The method of claim 1, wherein the biological activity is the
level of expression of the polypeptide.
4. The method, according to claim 1, wherein the biological
activity is the level of expression of an mRNA molecule encoding
the IAP polypeptide.
5. The method, according to claim 1, wherein the biological
activity is an apoptosis inhibiting activity.
6. The method of claim 3, wherein the level of expression is
measured by assaying the amount of the IAP polypeptide present in
the cell.
7. The method of claim 1, wherein the IAP polypeptide is selected
from the group consisting of: HIAP-1, m-HIAP-1, HIAP-2, m-HIAP-2,
XIAP, and m-XIAP.
8. The method of claim 1, wherein the IAP polypeptide is XIAP.
9. The method of claim 1, wherein the IAP polypeptide is
HIAP-1.
10. The method of claim 1, wherein the IAP polypeptide is
HIAP-2.
11. The method of claim 1, wherein the compound is a negative
regulator of an IAP-dependent anti-apoptotic pathway.
12. The method of claim 1, wherein the compound is a fragment of
the IAP polypeptide, said fragment comprising at least one BIR
domain and a ring zinc finger domain.
13. The method of claim 1, wherein the compound is a compound that
prevents enhances cleavage of the IAP polypeptide.
14. The method of claim 1, wherein the compound is a purified
antibody or a fragment thereof that specifically binds to the IAP
polypeptide.
15. The method of claim 1, wherein the compound is a ribozyme.
16. The method of claim 1, wherein the compound is an antisense
nucleic acid molecule have a nucleic acid sequence that is
complementary to the coding strand of a nucleic acid sequence
encoding the IAP polypeptide.
17. The method of claim 13, wherein the cleavage is decreased by at
least 20% in the cell.
18. The method of claim 14, wherein the antibody binds to a BIR
domain of the IAP polypeptide.
19. The method of claim 16, wherein the nucleic acid sequence
encoding the IAP polypeptide has about 50% or greater identity with
the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO:
7, SEQ ID NO: 9, SEQ ID NO: 11, or SEQ ID NO: 13.
20. The method of claim 16, wherein the antisense nucleic acid
molecule decreases the level of the nucleic acid sequence encoding
the IAP polypeptide by at least 20%, the level being measured in
the cytoplasm of the cell.
21. The method of claim 16, wherein the antisense nucleic acid
molecule is encoded by a virus vector.
22. The method of claim 16, wherein the antisense nucleic acid
molecule is encoded by a transgene.
23. The method of claim 1, wherein the mammal is a human or a
mouse.
24. The method of claim 1, wherein the proliferative disease is
cancer.
25. The method of claim 24, wherein the cancer is in a tissue
selected from the group consisting of: ovary, breast, pancreas,
lymph node, skin, blood, lung, brain, kidney, liver, nasopharyngeal
cavity, thyroid, central nervous system, prostate, colon, rectum,
cervix, endometrium, and lung.
26. A method of inducing apoptosis in a cell in a mammal diagnosed
as having a proliferative disorder, the method comprising:
administering to the mammal an antisense nucleic acid which
inhibits the biological activity of an inhibitor apoptosis (IAP),
wherein the antisense is complimentary to a mammalian IAP nucleic
acid sequence encoding an IAP polypeptide selected from the group
consisting of: a human XIAP-1 (SEQ ID 3), XIAP-1 (SEQ ID 5), XIAP-2
(SEQ ID 7) m-XIAP-1(SEQ ID 9), HIAP-1 (SEQ ID 11), and HIAP-2 (SEQ
ID 13).
27. The method of claim 26, in which the mammal is a human.
28. The method of claim 26, in which the proliferative disease is
cancer.
29. The method of claim 28, in which the cancer is ovarian cancer,
adinocarcenoma, lymphoma or pancreatic cancer.
30. The method of claim 26, in which the biological activity is
inhibition of apoptosis.
31. The method of claim 26 in which the IAP biological activity is
inhibited by at least 25%.
32. The method of claim 26 in which the IAP is HIAP-1.
33. The method of claim 26 in which the IAP is HIAP-2.
34. The method of claim 26 in which the IAP is XIAP.
35. The method of claim 26 in which the mammal is a human.
36. The method of claim 26 in which the cell is proliferating in
the proliferative disease.
37. A method of treating a patient diagnosed as having a
proliferative disease, the method comprising: administering to the
patient: an administering to the patient an antisense nucleic acid
which inhibits the biological activity of an inhibitor apoptosis
(IAP), wherein the antisense is complimentary to a mammalian IAP
nucleic acid sequence encoding an IAP polypeptide selected from the
group consisting of: a human XIAP-1 (SEQ ID 3), XIAP-1 (SEQ ID 5),
XIAP-2 (SEQ ID 7) m-XIAP-1(SEQ ID 9), HIAP-1 (SEQ ID 11), and
HIAP-2 (SEQ ID 13).
38. The method of claim 37, wherein the mammal is a human.
39. The method of claim 37, wherein the proliferative disease is
cancer.
40. The method of claim 39, wherein the cancer is ovarian cancer,
adenocarcinoma, lymphoma, or pancreatic cancer.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S.
application Ser. No. 09/974,592, filed Oct. 9, 2001 (now allowed),
which is a continuation application of U.S. application Ser. No.
09/617,053, filed Jul. 14, 2000 (now U.S. Pat. No. 6,300,492),
which is a continuation application of U.S. application Ser. No.
08/800,929, filed Feb. 13, 1997 (now U.S. Pat. No. 6,133,437).
BACKGROUND OF THE INVENTION
[0002] The invention relates to the diagnosis and treatment of
cancer.
[0003] One way by which cells die is referred to as apoptosis, or
programmed cell death. Apoptosis often occurs as a normal part of
the development and maintenance of health tissues. The process
occurs so rapidly that it is difficult to detect. This may help to
explain why the involvement of apoptosis in a wide spectrum of
biological processes has only recently been recognized.
[0004] The apoptosis pathway is now known to play a critical role
in embryonic development, viral pathogenesis, cancer, autoimmune
disorders, and neurodegenerative disease. The failure of an
apoptotic response has been implicated in the development of
cancer, autoimmune disorders, such as lupus erythematosis and
multiple sclerosis, and in viral infections, including those
associated with herpes virus, poxvirus, and adenovirus.
[0005] Baculoviruses encode proteins that are termed inhibitors of
apoptosis proteins (IAPs) because they inhibit the apoptosis that
would otherwise occur when insect cells are infected by the virus.
These proteins are thought to work in a manner that is independent
of other viral proteins. The baculovirus IAP genes include
sequences encoding a ring zinc finger-like motif (RZF), which is
presumed to be directly involved in DNA binding, and two N-terminal
domains that consist of a 70 amino acid repeat motif termed a BIR
domain (Baculovirus IAP Repeat).
[0006] The role of apoptosis in cancer has only recently been
appreciated. The identification of growth promoting "oncogenes" in
the late 1970's gave rise to an almost universal focus on cellular
proliferation that dominated research in cancer biology for many
years. Long-standing dogma held that anti-cancer therapies
preferentially targeted rapidly dividing cancer cells relative to
"normal" cells. This explanation was not entirely satisfactory,
since some slow growing tumors are easily treated, while many
rapidly dividing tumor types are extremely resistant to anti-cancer
therapies. Progress in the cancer field has now led to a new
paradigm in cancer biology wherein neoplasia is viewed as a failure
to execute normal pathways of programmed cell death. Normal cells
receive continuous feedback from their neighbors through various
growth factors, and commit "suicide" if removed from this context.
Cancer cells somehow ignore these commands and continue
inappropriate proliferation. Cancer therapies, including radiation
and many chemotherapies, have traditionally been viewed as causing
overwhelming cellular injury. New evidence suggests that cancer
therapies actually work by triggering apoptosis.
[0007] Both normal cell types and cancer cell types display a wide
range of susceptibility to apoptotic triggers, although the
determinants of this resistance are only now under investigation.
Many normal cell types undergo temporary growth arrest in response
to a sub-lethal dose of radiation or cytotoxic chemical, while
cancer cells in the vicinity undergo apoptosis. This provides the
crucial treatment "window" of appropriate toxicity that allows
successful anticancer therapy. It is therefore not surprising that
resistance of tumor cells to apoptosis is emerging as a major
category of cancer treatment failure.
[0008] Compared to the numerous growth promoting oncogenes
identified to date (>100) relatively few genes have been
isolated that regulate apoptosis. The Bcl-2 gene was first
identified as an oncogene associated with the development of
follicular lymphomas. In contrast to all other oncogenes identified
to date, Bcl-2 displays no ability to promote cell proliferation,
and instead has been demonstrated to suppress apoptosis by a
variety of triggers. Elevated bcl-2 expression is associated with a
poor prognosis in neuroblastoma, prostate and colon cancer, and can
result in a multidrug resistant phenotype in vitro. Although the
study of Bcl-2 has helped revolutionize cancer paradigms, the vast
majority of human malignancies do not demonstrate aberrant Bcl-2
expression.
[0009] In contrast to the findings with bcl-2, mutation of the p53
tumor suppresser gene has been estimated to occur in up to 50% of
human cancers and is the most frequent genetic change associated
with cancer to date. The p53 protein plays a crucial role in
surveying the genome for DNA damage. The cell type and degree of
damage determines whether the cell will undergo growth arrest and
repair, or initiate apoptosis. Mutations in p53 interfere with this
activity, rendering the cell resistant to apoptosis by a wide range
of cellular insults. Some progress has been made in understanding
the molecular biology of p53, but many questions remain. p53 is
known to function as a transcription factor, with the ability to
positively or negatively regulate the expression of a variety of
genes involved in cell cycle control, DNA repair, and apoptosis
(including the anti-apoptotic Bcl-2 gene described above and the
related proapoptotic gene bax). The drug resistant phenotype
conferred by p53 alterations has been linked to Bcl-2/Bax
regulation, but this correlation does not hold for most cancer
types, leaving open the possibility that other critical genes
regulated by p53 remain to be identified.
SUMMARY OF THE INVENTION
[0010] We have discovered that IAP and NAIP overexpression are
associated with a wide range of cancer types including ovarian
cancer, adenocarcinoma, lymphoma; and pancreatic cancer. In
addition, we have found that nuclear localization fragmentation of
the IAPs, and overexpression of the IAPs in the presence of p53
mutations correlate with a cancer diagnosis, a poor prognosis, and
resistance to numerous chemotherapeutic cancer drugs. These
discoveries provide diagnostic, prognostic, and therapeutic
compounds and methods for the detection and treatment of
proliferative diseases.
[0011] In the first aspect, the invention features a method of
detecting cancer or an increased likelihood of cancer by detecting
an increase IAP gene expression or protein expression in a cell
from the mammal. In various embodiments, the detection may be
performed by contacting with IAP or NAIP nucleic acid, or a portion
thereof (which is greater than 9 nucleotides, and preferably
greater than 18 nucleotides in length), with a preparation of
nucleic acid from the cell; detecting levels of IAP or NAIP nucleic
acid using quantitative nucleic acid amplification techniques;
monitoring the levels of IAP or NAIP protein; or monitoring the
levels of IAP or NAIP biological activity. Preferably, the cell is
a cell from a mammal suspected of having a leukemia, a lymphoma,
breast cancer, pancreatic cancer, melanoma, lung cancer, or ovarian
cancer.
[0012] In one embodiment utilizing nucleic acid amplification for
detection, the invention features characterization of a cellular
IAP or NAIP nucleic acid content and levels by: (a) providing a
sample of nucleic acid; (b) providing a pair of oligonucleotides
having sequence homology to an IAP or NAIP nucleic acid; (c)
combining the pair of oligonucleotides with the cellular sample
under conditions suitable for polymerase chain reaction-mediated
nucleic acid amplification; and (d) isolating the amplified IAP
nucleic acid or fragment thereof. The isolated nucleic acid may
then be quantitated, sequenced, or otherwise characterized for the
activity it imparts on the cell or related-cells. In preferred
embodiments, the amplification is carried out using a
reverse-transcription polymerase chain reaction, for example, the
RACE method.
[0013] In one embodiment using nucleic acid hybridization for
detection, the invention features use of IAP or NAIP nucleic acid
isolated according to the method involving: (a) providing a
preparation of nucleic acid; (b) providing a detectably-labelled
nucleotide sequence having homology to a region of an IAP or NAIP
nucleic acid; (c) contacting the preparation of nucleic acid with
the detectably-labelled nucleic acid sequence under hybridization
conditions providing detection of nucleic acid having 50% or
greater nucleotide sequence identity; and (d) identifying IAP or
NAIP and characterizing nucleic acid by their association with the
detectable label.
[0014] In one embodiment utilizing antibodies for detection, the
invention features methods for using a purified antibody that binds
specifically to an IAP or NAIP family of proteins. Such an antibody
may be used for diagnosis and also for drug screens, prognostic
methods, and treatment methods described herein. Any standard
immunodetection method may be employed, as appropriate. Preferably,
the antibody binds specifically to XIAP, HIAP-1, HIAP-2 or NAIP. In
various embodiments, the antibody may react with other IAP
polypeptides or may be specific for one or a few IAP polypeptides.
The antibody may be a monoclonal or a polyclonal antibody.
Preferably, the antibody reacts specifically with only one of the
IAP polypeptides, for example, reacts with murine and human xiap,
but not with hiap-1 or hiap-2 from other mammalian species. In any
of the immunodetection, diagnostic and prognostic methods an
increase in IAP or NAIP polypeptide levels or an increase in the
level of certain IAP or NAIP fragments described herein (e.g.,
BIR-containing fragments or nuclear polypeptides, found to be
associated with proliferation indicate a cancer diagnosis or a poor
cancer prognosis when therapeutics which act by enhancing apoptosis
are used for treatment.
[0015] In another aspect, the invention features an IAP or NAIP
antisense oligonucleotide for use in suppressing cell
proliferation. Such nucleic acids of the invention and methods for
using them may be identified according to a method involving: (a)
providing a cell sample; (b) introducing by transformation into the
cell sample a candidate IAP or NAIP antisense oligonucleotide; (c)
expressing the candidate IAP or NAIP antisense oligonucleotide
within the cell sample; and (d) determining whether the cell sample
exhibits an altered apoptotic response, whereby increased apoptosis
identifies an anti-proliferative compound. Preferably, the cell is
a cancer cell.
[0016] In another aspect, the invention features a method of
determining the prognosis of a mammal having a proliferative
disease. The method includes detecting levels of IAP or NAIP
nucleic acids, protein levels, or biological activity, or IAP
fragments in the cell suspected to be involved in a proliferative
disease. In various embodiments, the methods of detection described
above for diagnosis may be employed. An increase in IAP or NAIP
levels indicates a proliferative disease (i.e., an increased
likelihood the cancers described herein) and, particularly if a p53
mutation is present, a poor prognosis for therapeutic approaches
which rely on enhancing apoptosis. The presence of IAP fragments of
less than 64 kD, more preferably less than 45 kD indicates in
increased likelihood that the cancer will be resistant to
chemotherapeutics which act by inducing 10 apoptosis.
[0017] In preferred embodiments of the diagnostic and prognostic
methods, the levels being monitored are levels of IAP or NAIP
express or activity levels known to be associated with cancer
suspected or diagnosed. Most preferably, the disease is selected
from the group consisting of a breast cancer (preferably using a
hiap-2, hiap-1, HIAP-2, or HIAP-1 probe), ovarian cancer
(preferably using a hiap-2, or HIAP-2 probe), promyelocytic
leukemia, a HeLa-type carcinoma, chronic myelogenous leukemia
(preferably using a xiap, hiap-2, XIAP or HIAP-2 probe),
lymphoblastic leukemia (preferably using a xiap or XIAP probes),
Burkitt's lymphoma (preferably using a hiap-1 or HIAP-1 probe),
colorectal adenocarcinoma, lung carcinoma, and melanoma (preferably
using a xiap, or XIAP probe). Preferably, a cancer diagnosis or
poor prognosis is indicated by a 2-fold increase in expression or
activity, more preferably, at least a 10-fold increase in
expression or activity in the cell being tested.
[0018] In another aspect, the invention features a method of
identifying a compound that inhibits cancer by enhancing apoptosis.
The method includes providing a cell expressing an IAP or NAIP
polypeptide and being capable of proliferation or viability in
culture, contacting the cell with a candidate compound, and
monitoring the expression of an IAP gene, NAIP gene, a reporter
linked to IAP or NAIP regulatory sequence, levels of IAP or NAIP
polypeptides, cleavage of IAP polypeptides, and/or nuclear versus
cytoplasmic localization of IAP or NAIP polypeptides. A decrease in
the level of expression of the IAP or NAIP gene, IAP or NAIP
protein characteristics, IAP or NAIP biological activity, IAP
cleavage, or localization of protein to the nucleus, indicate the
presence of a compound which enhances apoptosis, as described
herein. In various preferred embodiments, the cell used in the
method is a fibroblast, a neuronal cell, a glial cell, a lymphocyte
(T cell or B cell), a breast cancer cell, a lymphoma cell, an
ovarian cancer cell, a leukemia cell, a pancreatic cancer cell, a
melanoma cell, or an insect cell; the preferred polypeptide
expression being monitored is XIAP, HIAP-1, HIAP-2, or NAIP (i.e.,
human or murine). In the embodiment utilizing fragment detection,
the fragment is preferably less than 64 kD, more preferably less
than 45 kD. All the detection methods described herein may be
employed, as appropriate.
[0019] In a related aspect, the invention features methods of
detecting compounds that enhance apoptosis using the interaction
trap technology and IAP or NAIP polypeptides, or fragments thereof,
as a component of the bait. In preferred embodiments, the compound
being tested as an enhancer of apoptosis is also a polypeptide.
[0020] In another aspect, the invention features a method of
treating a patient diagnosed with a proliferative disease. In the
method, apoptosis may be induced in a cell to control a
proliferative disease either alone or in combination with other
therapies by administering to the cell a negative regulator of the
IAP-dependent or NAIP anti-apoptotic pathway. The negative
regulator may be, but is not limited to, an IAP ring zinc finger,
and an IAP polypeptide that includes a ring zinc finger and lacks
at least one BIR domain. Alternatively, apoptosis may be induced in
the cell by administering a nucleic acid encoding an IAP antisense
oligonucleotide administered directly or via gene therapy (see U.S.
Pat. No. 5,576,208 for general parameters which may be applicable
in the selection of IAP or NAIP antisense oligonucleotides).
[0021] The term "oligonucleotide" refers to an oligomer or polymer
of ribonucleic acid or deoxyribonucleic acid. This term includes
oligomers consisting of naturally occurring bases, sugars and
intersugar (backbone) linkages as well as oligomers having
non-naturally occurring portions which function similarly. Such
modified or substituted oligonucleotides are often preferred over
native forms because of properties such as, for example, enhanced
cellular uptake and increased stability in the presence of
nucleases.
[0022] Specific examples of some preferred oligonucleotides
envisioned for this invention may contain phosphorothioates,
phosphotriesters, methyl phosphonates, short chain alkyl or
cycloalkyl intersugar linkages or short chain heteroatomic or
heterocyclic intersugar linkages. Most preferred are those with
CH.sub.2--NH--O--CH.sub.2, CH.sub.2--N(CH.sub.3)--O--CH.sub.2,
CH.sub.2--O--N(CH.sub.3)--CH.sub.2,
CH.sub.2--N(CH.sub.3)--N(CH.sub.3)--CH.sub.2 and
O--N(CH.sub.3)--CH.sub.2--CH.sub.2 backbones (where phosphodiester
is O--P--O--CH.sub.2). Also preferred are oligonucleotides having
morpholino backbone structures. Summerton, J. E. and Weller, D. D.,
U.S. Pat. No. 5,034,506. In other preferred embodiments, such as
the protein-nucleic acid (PNA) backbone, the phosphodiester
backbone of the oligonucleotide may be replaced with a polyamide
backbone, the bases being bound directly or indirectly to the aza
nitrogen atoms of the polyamide backbone. P. E. Nielsen, M. Egholm,
R. H. Berg, O Buchardt, Science 199, 254, 1497. Other preferred
oligonucleotides may contain alkyl and halogen-substituted sugar
moieties comprising one of the following at the 2' position: OH,
SH, SCH.sub.3, F, OCN, O(CH.sub.2).sub.n NH.sub.2 or O(CH.sub.2).
CH.sub.3 where n is from 1 to about 10; C.sub.1 to C.sub.10 lower
alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN;
CF.sub.3; OCF.sub.3; O--S--, or N-alkyl; O--, S--, or N-alkenyl;
SOCH.sub.3; SO.sub.2 CH.sub.3; ONO.sub.2; NO.sub.2; N.sub.3;
NH.sub.2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino;
polyalkylamino; substituted silyl; an RNA cleaving group; a
conjugate; a reporter group; an intercalator; a group for improving
the pharmacokinetic properties of an oligonucleotide; or a group
for improving the pharmacodynamic properties of an oligonucleotide
and other substituents having similar properties. Oligonucleotides
may also have sugar mimetics such as cyclobutyls in place of the
pentofuranosyl group.
[0023] Other preferred embodiments may include at least one
modified base form. Some specific examples of such modified bases
include 2-amino)adenine, 2-(methylamino)adenine,
2-(imidazolylalkyl)adenine, 2-aminoalklyamino)adenine or other
heterosubstituted alkyladenines. In yet another method, the
negative regulator may be a purified antibody, or a fragment
thereof, that binds specifically to an IAP polypeptide. For
example, in one preferred embodiment, the antibody may bind to an
approximately 26 kDa cleavage product of an IAP polypeptide that
includes at least one BIR domain but lacks a ring zinc finger
domain.
[0024] In two additional aspects, the invention features a
transgenic animal and methods of using the mammal for detection of
anti-cancer therapeutics. Preferably the mammal overexpresses an
IAP or NAIP polypeptide and/or expresses a NAIP or IAP antisense
oligonucleotide or IAP or NAIP fragment In one embodiment, the
animal also has a genetic predisposition to cancer or has cancer
cells under conditions which provide for proliferation absent the
transgenic construct encoding either the antisense oligonucleotide
or fragment.
[0025] By "IAP gene" is meant a gene encoding a polypeptide having
at least one BIR domain and a ring zinc finger domain which is
capable of modulating (inhibiting or enhancing) apoptosis in a cell
or tissue when provided by other intracellular or extracellular
delivery methods (see, e.g., U.S.S.Ns. 08/511,485, 08/576,965, and
PCT/IB96/01022). In preferred embodiments the IAP gene is a gene
having about 50% or greater nucleotide sequence identity to at
least one of the IAP amino acid encoding sequences of FIGS. 1-4 or
portions thereof. Preferably, the region of sequence over which
identity is measured is a region encoding at least one BIR domain
and a ring zinc finger domain. Mammalian IAP genes include
nucleotide sequences isolated from any mammalian source.
Preferably, the mammal is a human. The term "IAP gene" is meant to
encompass any member of the family of genes that encode inhibitors
of apoptosis. An IAP gene may encode a polypeptide that has at
least 20%, preferably at least 30%, and most preferably at least
50% amino acid sequence identity with at least one of the conserved
regions of one of the IAP members described herein (i.e., either
the BIR or ring zinc finger domains from the human or murine xiap,
hiap-1 and hiap-2). Representative members of the IAP gene family
include, without limitation, the human and murine xiap, hiap-1, and
hiap-2 genes.
[0026] By "IAP protein" or "IAP polypeptide" is meant a
polypeptide, or fragment thereof, encoded by an IAP gene.
[0027] "NAIP gene" and "NAIP polypeptide" means the NAIP genes,
fragments thereof, and polypeptides encoded by the same described
in UK9601108.5 filed Jan. 19, 1996 and the PCT application claiming
priority from UK9601108.5 filed Jan. 17, 1997.
[0028] By "BIR domain" is meant a domain having the amino acid
sequence of the consensus sequence:
Xaa1-Xaa1-Xaa1-Arg-Leu-Xaa1-Thr-Phe-Xaa1-Xaa1-TrpPro-Xaa2-Xaa1-Xaa1-Xaa2--
Xaa2-Xaa1-Xaa1-Xaa1-Xaa1-Leu-Ala-Xaa1-Ala-Gly-Phe-Tyr-Tyr-Xaa1-Gly-Xaa1-Xa-
a1-Asp-Xaa1-Val-Xaa1-Cys-Phe-Xaa1-Cys-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-Trp-Xa-
a1-Xaa1-Xaa1-Asp-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-His-Xaa1-Xaa1-Xaa1-Xaa1-Pro-Xaa1-
-Cys-Xaa1-Phe-Val, wherein Xaa1 is any amino acid and Xaa2 is any
amino acid or is absent (SEQ ID NO:2). Preferably, the sequence is
substantially identical to one of the BIR domain sequences provided
for xiap, hiap-1, hiap-2 herein.
[0029] By "ring zinc finger" or "RZF" is meant a domain having the
amino acid sequence of the consensus sequence:
Glu-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-Xaa2-Xaa1-Xaa1-Xaa1-Cys-Lys-Xaa3-Cys-Me-
t-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-Xaa3-Xaa1-Phe-Xaa1-Pro-Cys-Gly-His-Xaa1-Xaa1-Xa-
a1-Cys-Xaa1-Xaa1-Cys-Ala-Xaa1-Xaa1-Xaa1-Xaa1-Xaa1-Cys-Pro-Xaa1-Cys,
wherein Xaa1 is any amino acid, Xaa2 is Glu or Asp, and Xaa3 is Val
or Ile (SEQ ID NO:1).
[0030] Preferably, the sequence is substantially identical to the
RZF domains provided herein for the human or murine Xiap, Hiap-1,
or Hiap-2.
[0031] By "enhancing apoptosis" is meant increasing the number of
cells which apoptose in a given cell population. Preferably, the
cell population is selected from a group including ovarian cancer
cells, breast cancer cells, pancreatic cancer cells, T cells,
neuronal cells, fibroblasts, or any other cell line known to
proliferate in a laboratory setting. It will be appreciated that
the degree of apoptosis enhancement provided by an apoptosis
enhancing compound in a given assay will vary, but that one skilled
in the art can determine the statistically significant change in
the level of apoptosis which identifies a compound which enhances
apoptosis otherwise limited by an IAP. Preferably, "enhancing
apoptosis" means that the increase in the number of cells
undergoing apoptosis is at least 25%, more preferably the increase
is 50%, and most preferably the increase is at least one-fold.
Preferably, the sample monitored is a sample of cells which
normally undergo insufficient apoptosis (i.e., cancer cells).
[0032] By "proliferative disease" is meant a disease which is
caused by or results in inappropriately high levels of cell
division, inappropriately low levels of apoptosis, or both. For
example, cancers such as lymphoma, leukemia, melanoma, ovarian
cancer, breast cancer, pancreatic cancer, and lung cancer are all
examples of proliferative disease.
[0033] By "polypeptide" is meant any chain of more than two amino
acids, regardless of post-translational modification such as
glycosylation or phosphorylation.
[0034] By "IAP or NAIP biological activity" is meant any activity
known to be caused in vivo or in vitro by a NAIP or IAP
polypeptide.
[0035] By "substantially identical" is meant a polypeptide or
nucleic acid exhibiting at least 50%, preferably 85%, more
preferably 90%, and most preferably 95% homology to a reference
amino acid or nucleic acid sequence. For polypeptides, the length
of comparison sequences will generally be at least 16 amino acids,
preferably at least 20 amino acids, more preferably at least 25
amino acids, and most preferably 35 amino acids. For nucleic acids,
the length of comparison sequences will generally be at least 50
nucleotides, preferably at least 60 nucleotides, more preferably at
least 75 nucleotides, and most preferably 10 nucleotides.
[0036] Sequence identity is typically measured using sequence
analysis software with the default parameters specified therein
(e.g., Sequence Analysis Software Package of the Genetics Computer
Group, University of Wisconsin Biotechnology Center, 1710
University Avenue, Madison, Wis. 53705). This software program
matches similar sequences by assigning degrees of homology to
various substitutions, deletions, and other modifications.
Conservative substitutions typically include substitutions within
the following groups: glycine, alanine, valine, isoleucine,
leucine; aspartic acid, glutamic acid, asparagine, glutamine;
serine, threonine; lysine, arginine; and phenylalanine,
tyrosine.
[0037] By "substantially pure polypeptide" is meant a polypeptide
that has been separated from the components that naturally
accompany it. Typically, the polypeptide is substantially pure when
it is at least 60%, by weight, free from the proteins and
naturally-occurring organic molecules with which it is naturally
associated. Preferably, the polypeptide is an IAP polypeptide that
is at least 75%, more preferably at least 90%, and most preferably
at least 99%, by weight, pure. A substantially pure IAP polypeptide
may be obtained, for example, by extraction from a natural source
(e.g., a fibroblast, neuronal cell, or lymphocyte) by expression of
a recombinant nucleic acid encoding an IAP polypeptide, or by
chemically synthesizing the protein. Purity can be measured by any
appropriate method, e.g., by column chromatography, polyacrylamide
gel electrophoresis, or HPLC analysis.
[0038] A protein is substantially free of naturally associated
components when it is separated from those contaminants which
accompany it in its natural state. Thus, a protein which is
chemically synthesized or produced in a cellular system different
from the cell from which it naturally originates will be
substantially free from its naturally associated components.
Accordingly, substantially pure polypeptides include those derived
from eukaryotic organisms but synthesized in E. coli or other
prokaryotes.
[0039] By "substantially pure DNA" is meant DNA that is free of the
genes which, in the naturally-occurring genome of the organism from
which the DNA of the invention is derived, flank the gene. The term
therefore includes, for example, a recombinant DNA which is
incorporated into a vector; into an autonomously replicating
plasmid or virus; or into the genomic DNA of a prokaryote or
eukaryote; or which exists as a separate molecule (e.g., a cDNA or
a genomic or cDNA fragment produced by PCR or restriction
endonuclease digestion) independent of other sequences. It also
includes a recombinant DNA which is part of a hybrid gene encoding
additional polypeptide sequence.
[0040] By "transformed cell" is meant a cell into which (or into an
ancestor of which) has been introduced, by means of recombinant DNA
techniques, a DNA molecule encoding (as used herein) an IAP
polypeptide.
[0041] By "transgene" is meant any piece of DNA which is inserted
by artifice into a cell, and becomes part of the genome of the
organism which develops from that cell. Such a transgene may
include a gene which is partly or entirely heterologous (i.e.,
foreign) to the transgenic organism, or may represent a gene
homologous to an endogenous gene of the organism.
[0042] By "transgenic" is meant any cell which includes a DNA
sequence which is inserted by artifice into a cell and becomes part
of the genome of the organism which develops from that cell. As
used herein, the transgenic organisms are generally transgenic
mammalian (e.g., rodents such as rats or mice) and the DNA
(transgene) is inserted by artifice into the nuclear genome.
[0043] By "transformation" is meant any method for introducing
foreign molecules into a cell. Lipofection, calcium phosphate
precipitation, retroviral delivery, electroporation, and biolistic
transformation are just a few of the teachings which may be used.
For example, biolistic transformation is a method for introducing
foreign molecules into a cell using velocity driven
microprojectiles such as tungsten or gold particles. Such
velocity-driven methods originate from pressure bursts which
include, but are not limited to, helium-driven, air-driven, and
gunpowder-driven techniques. Biolistic transformation may be
applied to the transformation or transfection of a wide variety of
cell types and intact tissues including, without limitation,
intracellular organelles (e.g., and mitochondria and chloroplasts),
bacteria, yeast, fungi, algae, animal tissue, and cultured
cells.
[0044] By "positioned for expression" is meant that the DNA
molecule is positioned adjacent to a DNA sequence which directs
transcription and translation of the sequence (i.e., facilitates
the production of, e.g., an IAP polypeptide, a recombinant protein
or a RNA molecule).
[0045] By "reporter gene" is meant a gene whose expression may be
assayed; such genes include, without limitation, glucuronidase
(GUS), luciferase, chloramphenicol transacetylase (CAT), and
.beta.-galactosidase.
[0046] By "promoter" is meant minimal sequence sufficient to direct
transcription. Also included in the invention are those promoter
elements which are sufficient to render promoter-dependent gene
expression controllable for cell type-specific, tissue-specific or
inducible by external signals or agents; such elements may be
located in the 5' or 3' regions of the native gene.
[0047] By "operably linked" is meant that a gene and one or more
regulatory sequences are connected in such a way as to permit gene
expression when the appropriate molecules (e.g., transcriptional
activator proteins are bound to the regulatory sequences).
[0048] By "conserved region" is meant any stretch of six or more
contiguous amino acids exhibiting at least 30%, preferably 50%, and
most preferably 70% amino acid sequence identity between two or
more of the IAP family members, (e.g., between human HIAP-1,
HIAP-2, and XIAP). Examples of preferred conserved regions are
shown (as boxed or designated sequences) in FIGS. 5-7 and Tables 1
and 2, and include, without limitation, BIR domains and ring zinc
finger domains.
[0049] By "detectably-labelled" is meant any means for marking and
identifying the presence of a molecule, e.g., an oligonucleotide
probe or primer, a gene or fragment thereof, or a cDNA molecule.
Methods for detectably-labelling a molecule are well known in the
art and include, without limitation, radioactive labelling (e.g.,
with an isotope such as .sup.32P or .sup.35S) and nonradioactive
labelling (e.g., chemiluminescent labelling, e.g., fluorescein
labelling).
[0050] By "antisense," as used herein is meant an oligonucleotide,
regardless of length, that is complementary to the coding strand of
an IAP or NAIP gene. Preferably, the antisense oligonucleotide is
capable of enhancing apoptosis when present in a cell which
normally does not undergo sufficient apoptosis. Preferably, the
increase is at least 10%, relative to a control, more preferably
25%, and most preferably 1-fold or more.
[0051] By "purified antibody" is meant antibody which is at least
60%, by weight, free from proteins and naturally occurring organic
molecules with which it is naturally associated. Preferably, the
preparation is at least 75%, more preferably 90%, and most
preferably at least 99%, by weight, antibody, e.g., an IAP specific
antibody. A purified antibody may be obtained, for example, by
affinity chromatography using recombinantly-produced protein or
conserved motif peptides and standard techniques.
[0052] By "specifically binds" is meant an antibody that recognizes
and binds a protein but that does not substantially recognize and
bind other molecules in a sample, e.g., a biological sample, that
naturally includes protein.
[0053] Other features and advantages of the invention will be
apparent from the following description of the preferred
embodiments thereof, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0054] FIG. 1 is the human xiap cDNA sequence (SEQ ID NO:3) and the
XIAP polypeptide sequence (SEQ ID NO:4).
[0055] FIG. 2 is the human hiap-1 cDNA sequence (SEQ ID NO:5) and
the HIAP-1 polypeptide sequence (SEQ ID NO:6).
[0056] FIG. 3 is the human hiap-2 cDNA sequence (SEQ ID NO:7) and
the HIAP-2 polypeptide sequence (SEQ ID NO:8). The sequence absent
in the hiap-2-A variant is boxed.
[0057] FIG. 4 is the murine xiap (also referred to as "miap-3")
cDNA sequence (SEQ ID NO:9) and encoded murine XIAP polypeptide
sequence (SEQ ID NO:10).
[0058] FIG. 5 is the murine hiap-1 (also referred to as "miap-1")
cDNA sequence (SEQ ID NO: 11) and the encoded murine HIAP-1
polypeptide sequence (SEQ ID NO:12).
[0059] FIG. 6 is the murine hiap-2 (also referred to as "miap-2")
cDNA sequence (SEQ ID NO:13) and the encoded murine HIAP-2
polypeptide (SEQ ID NO:14).
[0060] FIG. 7 is a photograph of a Northern blot illustrating human
hiap-1 and hiap-2 mRNA expression in human tissues.
[0061] FIG. 8 is a photograph of a Northern blot illustrating human
hiap-2 mRNA expression in human tissues.
[0062] FIG. 9 is a photograph of a Northern blot illustrating human
xiap mRNA expression in human tissues.
[0063] FIGS. 10A-10D are graphs depicting suppression of apoptosis
by XIAP, HIAP-1, HIAP-2, bcl-2, smn, and 6-myc.
[0064] FIG. 11 is a photograph of an agarose gel containing cDNA
fragments that were amplified, with hiap-1-specific primers, from
RNA obtained from Raji, Ramos, EB-3, Burkitt's lymphoma cells, and
Jiyoye cells, and cells from normal placenta.
[0065] FIG. 12 is a photograph of a Western blot containing protein
extracted from Jurkat and astrocytoma cells stained with an
anti-XIAP antibody. The position and size of a series of marker
proteins is indicated.
[0066] FIG. 13 is a photograph of a Western blot containing protein
extracted from Jurkat cells following treatment as described in
Example XII. The blot was stained with a rabbit polyclonal
anti-XIAP antibody. Lane 1, negative control; lane 2, anti-Fas
antibody; lane 3, anti-Fas antibody and cycloheximide; lane 4,
TNF-.alpha.; lane 5, TNF-.alpha. and cycloheximide.
[0067] FIG. 14 is a photograph of a Western blot containing protein
extracted from HeLa cells following exposure to anti-Fas
antibodies. The blot was stained with a rabbit polyclonal anti-XIAP
antibody. Lane 1, negative control; lane 2, cycloheximide; lane 3,
anti-Fas antibody; lane 4, anti-Fas antibody and cycloheximide;
lane 5, TNF-.alpha.; lane 6, TNF-.alpha. and cycloheximide.
[0068] FIGS. 15A and 15B are photographs of Western blots stained
with rabbit polyclonal anti-MAP antibody. Protein was extracted
from HeLa cells (FIG. 21A) and Jurkat cells (FIG. 21B) immediately,
1, 2, 3, 5, 10, and 22 hours after exposure to anti-Fas
antibody.
[0069] FIGS. 16A and 166B are photographs of Western blots stained
with an anti-CPP32 antibody (FIG. 16A) or a rabbit polyclonal
anti-XIAP antibody (FIG. 16B). Protein was extracted from Jurkat
cells immediately, 3 hours, or 7 hours after exposure to an
anti-Fas antibody. In addition to total protein, cytoplasmic and
nuclear extracts are shown.
[0070] FIG. 17 is a photograph of a polyacrylamide gel following
electrophoresis of the products of an in vitro XIAP cleavage
assay.
[0071] FIGS. 18 and 19 shows the increased level of HIAP-1 and
HIAP-2 mRNA, respectively, in breast cancer cell lines having p53
mutations (lanes 5-7). The bottom portion of the figure shows the
control.
[0072] FIG. 20 shows the influence of Taxol on DNA fragmentation in
Cisplatin-sensitive (right) and resistant (left) human ovarian
epithelial cancer cells.
[0073] FIG. 21 shows the influence of Cisplatin on DNA
fragmentation in sensitive (right) and resistant (left) human
ovarian epithelial cancer cells.
[0074] FIG. 22 shows the effects of Taxol on XIAP and Hiap-2
protein levels in Cisplatin sensitive (right) and resistant (left)
human ovarian epithelial cancer cells.
[0075] FIGS. 23A and 23B show the influence of Taxol and TGF.beta.
on HIAP-2 mRNA levels in Cisplatin sensitive (right) and resistant
(left) human epithelial cancer cells.
[0076] FIGS. 24A and 24B show the effect of TGF.beta. on XIAP
protein expression (FIG. 24A) and DNA fragmentation (FIG. 24B) in
Cisplatin sensitive and resistant cells.
DETAILED DESCRIPTION
[0077] Previously, we have provided a novel family of inhibitors of
apoptosis, the IAPs, and an additional related anti-apoptotic
protein, NAIP. Here we provide identification of cancer types in
which dysregulation of the IAPs and NAIP is apparent. Our results
are of paramount importance and provide diagnostics, prognostics,
treatments, and drug screens aimed at the detection and effective
treatment of cancer.
Cancer Screening
[0078] We initially studied IAP expression levels in a variety of
normal tissues and cancer cell lines using commercially available
northern blots. Elevated xiap, hiap-1 and hiap-2 mRNA was noted in
a surprising number of cancer lines of diverse lineage, including
colorectal cancer, lymphoma, leukemia, and melanoma cell lines. In
contrast, Bcl-2 mRNA was elevated in only a single cell line.
Although this result reinforced the importance of the IAPs in
cancer, the question remained as to whether the individual cancer
cell lines on the blot were representative of the cancer type. As a
result, we screened panels of cancer cell lines of particular tumor
type by northern blot and quantitative RT-PCR analysis in order to
ascertain the frequency of IAP dysregulation. The results are
summarized as follows:
Burkitt's Lymphoma
[0079] We studied both the frequency and consequences of IAP
upregulation in Burkitt's lymphoma. Elevated levels of hiap-1 and
hiap-2 have been found in the vast majority of the Burkitt's cell
lines examined. Furthermore, those Burkitt's lines expressing low
levels of hiap-1 are transcriptionally activated by Epstein-Barr
virus (EBV) infection.
Breast Adenocarcinoma
[0080] A key observation was made in this survey, in which a
correlation was observed between drug resistance, p53 status and
hiap-1/2 expression. Four of the cell lines possessed wild-type
p53, while three possessed documented p53 mutations that correlated
with resistance to the anti-cancer drug adriamycin. Significantly,
the three lines which were relatively more drug resistant also
displayed elevated hiap-1 and hiap-2 mRNA levels. These results
indicate that one of the ways that p53 controls apoptosis is
through regulation of these genes.
Ovarian Carcinoma
[0081] mRNA in situ analysis suggest a role for NAIP in the
developmental biology of the ovary. Overexpression of hiap-2 and
xiap mRNA has also been documented in some ovarian cancer cell
lines.
Pancreatic Cancer
[0082] Approximately 25% of the cell lines tested to date
demonstrate hiap-1 and hiap-2 mRNA elevation.
Summary of Cancer Panels
[0083] To date, a significant fraction of cancer cell lines of each
type examined display elevated IAP levels. Our results indicate
that hiap-1 and hiap-2 tend to be the most frequently and
dramatically upregulated. The apparent coordinate regulation of
both genes was surprising given their very different normal tissue
distribution. hiap-1 and hiap-2 reside in tandem array on
chromosome 11q23, a site frequently rearranged in lymphomas and
leukemias.
Transcriptional Regulation of the IAPs in Cancer Cell Lines
[0084] Our experiments have established a correlation between p53
status and transcriptional overexpression of hiap-1 and hiap-2.
This provides an important new way in which to enhance apoptosis,
particularly in view of the fact that the mechanism by which p53
controls cell fate remains largely unknown. It has-previously been
documented that wild-type p53 negatively down-regulates Bcl-2, and
positively upregulates the Bcl-2 antagonist Bax. In some cancer
cell types, mutation of p53 causes a two-fold effect; namely, the
upregulation of Bcl-2, and down regulation of Bax, both of which
contribute to the anti-apoptotic phenotype. While not wishing to
bind ourselves to a particular theory, we believe that wild-type
p53 also transcriptionally suppresses hiap-1 and hiap-2. DNA damage
that includes the increase in wild-type levels p53 levels would
therefore result in decreased hiap-1 and hiap-2 in normal cells,
resulting in apoptosis. Mutations in the p53 gene would therefore
result in a loss of transcriptional control of these iap genes. As
a result, p53 mutant cancer cells would display constitutively high
levels of hiap-1 and hiap-2, rendering the cells resistant to
anti-cancer therapies. The p53/hiap-1 and hiap-2 correlations may
be extended to the other cancer cell line panels. One may directly
demonstrate p53 regulation of the IAPs using transfection assays
and northern blot analysis.
[0085] Accordingly, we predict that cancer cells having p53
mutations (p53*) will have increased IAP levels resulting in a poor
response to chemotherapeutics. Because IAP levels may be assessed
more readily than the presence of a p53* mutation, our discovery
also provides an important improvement in cancer diagnosis and
prognosis (see below).
Transgenic Mice
[0086] We have constructed a number of IAP and NAIP transgenic
mouse expression vectors, including T-cell, B-cell, and neuronal
specific promoter constructs. Founder mice have been identified,
are viable, and for most of these constructs and we have developed
breeding colonies. These-mice will likely be prone to cancers of
the tissue types in which the promoter is active. Thus the mice
provide an excellent resource for testing the efficacy of
anti-sense oligos and for screening for apoptosis enhancing cancer
therapeutics. Standard mouse drug screening models and gene
delivery protocols may be employed to utilize the mice for this
purpose.
Diagnostic/Prognostic Reagents
[0087] There is a relative lack of diagnostic and prognostic tests
which clinical oncologists may utilize in determining the
appropriate degree of intervention in the treatment of cancer.
Mutation of the p53 gene remains one of the best prognostic
indicators in cancer biology. However, the number of different
mutations identified to date is great and scattered throughout the
gene. In addition, many mutations in p53 result in an inappropriate
stabilization of the protein, which allows detection at the protein
level rather than at the mRNA level. Mutations which alter the
transactivation/repression activities of the protein are not
necessarily apparent at either the mRNA or protein levels. On the
other hand, if IAP and NAIP expression levels correlate with p53
mutation they may provide more valuable prognostic information and
assist in the determination of which patients require more
aggressive treatment. Thus the invention provides two assays for
prognosis an diagnosis. Semi-quantitative RT-PCR based assays may
be used to assay for iap and/or naip gene or protein expression
levels. Alternatively, monoclonal antibodies may be incorporated
into an ELISA (enzyme linked immunosorbent assay) type assay for
direct determination of protein levels.
Therapeutic Products
[0088] For IAP related therapies one may employ the paradigms
utilized for Bcl-2 and RAS antisense development, although
accommodation of IAP mutation is not required (in contrast to ras
antisense). Most useful are antisense constructs which enhance
apoptosis at least 10%, preferably by enhancing degradation of the
RNA in the nucleus.
[0089] In addition to antisense approached described herein the
invention features small molecule screening assays which may be
used to identify lead compounds that negatively regulate the iaps.
For example, compounds which enhance apoptosis in the presence of
IAP overexpression or which decrease the level of IAP biological
activity may be detected and are useful cancer therapeutics.
[0090] Molecules that are found, by the methods described above, to
effectively modulate IAP gene expression or polypeptide activity
may be tested further in animal models. If they continue to
function successfully in an in vivo setting, they may be used as
therapeutics to either inhibit or enhance apoptosis, as
appropriate.
Manipulation of Cancer Chemotherapeutic Drug Resistance Using an
Antisense Oligonucleotide and Fragment Approaches
[0091] We have documented that overexpression of the IAPs renders
cell lines resistant to serum growth factor withdrawal, tumor
necrosis factor alpha (TNF) and menadione exposure, all of which
are treatments that normally induce apoptosis. Herein we describe
the extension of these studies to cancer cell lines using apoptotic
triggers used in clinical situations, such as doxorubicin,
adriamycin, and methotrexate. Our findings have led up to design
antisense oligonucleotide therapeutics. Rapid screening of multiple
cell lines for apoptotic response has been made feasible through
the generation of a series of sense and antisense adenoviral IAP
and NAIP expression vectors, as well as control lacZ viruses. One
may now show enhanced drug resistance using the expression
constructs. In addition, anti-sense adenovirus constructs may be
developed and used to test reversal of the drug resistant phenotype
of appropriate cell lines. We have surveyed cancer cell lines with
the objective of identifying tumor types in which IAP
overexpression is apparent or altered and these results are
described both above and in the Examples below. Concomitant to this
research, we have designed a series of antisense oligonucleotides
to various regions of each of the iaps. These oligonucleotides may
be used to enhance drug sensitivity after testing in an assay
system, i.e., with the adenoviral vectors system. Animal modeling
of the effectiveness of antisense IAP oligos may also be employed
as a step in testing and appropriate transgenic mammals for this
are described above and also generally available in the art.
[0092] The following describes some of the testing systems which
may be employed.
Anti-Cancer Gene Therapy
[0093] Retroviral vectors, adenoviral vectors, adeno-associated
viral vectors, or other viral vectors with the appropriate tropism
for cells likely requiring enhanced apoptosis (for example, breast
cancer and ovarian cancer cells) may be used as a gene transfer
delivery system for a therapeutic gene constructs. Numerous vectors
useful for this purpose are generally known (Miller, Human Gene
Therapy 15-14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis
and Anderson, BioTechniques 6:608-614, 1988; Tolstoshev and
Anderson, current opinion in Biotechnology 1:55-61, 1990; Sharp,
The Lancet 337:1277-1278, 1991, Cornetta et al., Nucleic Acid
Research and Molecular Biology 36:311-322, 1987; Anderson, Science
226:401-409, 1984; Moen, Blood Cells 17:407-416, 1991; Miller et
al., BioTechniques 7:980-990, 1989; Le Gal La Salle et al., Science
259:988-990, 1993; and Johnson, Chest 107:77 S-83S, 1995).
[0094] Retroviral vectors are particularly well developed and have
been used in clinical settings (Rosenberg et al., N. Engl. J. Med
323:370, 1990; Anderson et al., U.S. Pat. No. 5,399,346). Non-viral
approaches may also be employed for the introduction of therapeutic
DNA into cells otherwise predicted to undergo apoptosis. For
example, IAP may be introduced into a neuron or a T cell by
lipofection (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413,
1987; Ono et al., Neurosci. Lett. 117:259, 1990; Brigham et al.,
Am. J. Med. Sci. 298:278, 1989; Staubinger et al., Meth. Enz.
101:512, 1983), asialorosonucoid-polylysine conjugation (Wu et al.,
J. Biol. Chem. 263:14621, 1988; Wu et al., J. Biol. Chem.
264:16985, 1989); or, less preferably, microinjection under
surgical conditions (Wolff et al., Science 247:1465, 1990).
[0095] For any of the methods of application described above, the
therapeutic nucleic acid construct is preferably applied to the
site of the needed apoptosis event (for example, by injection).
However, it may also be applied to tissue in the vicinity of the
predicted apoptosis event or to a blood vessel supplying the cells
predicted to require enhanced apoptosis.
[0096] In the constructs described, nucleic acid expression can be
directed from any suitable-promoter (e.g., the human
cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein
promoters), and regulated by any appropriate mammalian regulatory
element. For example, if desired, enhancers known to preferentially
direct gene expression in ovarian cells, breast tissue, neural
cells, T cells, or B cells may be used to direct expression. The
enhancers used could include, without limitation, those that are
characterized as tissue- or cell-specific in their expression.
Alternatively, if a clone used as a therapeutic construct,
regulation may be mediated by the cognate regulatory sequences or,
if desired, by regulatory sequences derived from a heterologous
source, including any of the promoters or regulatory elements
described above.
[0097] Less preferably, anti-cancer gene therapy is accomplished by
direct administration of the therapeutic mRNA or antisense IAP mRNA
to a cell that is expected to require enhanced apoptosis. The mRNA
may be produced and isolated by any standard technique, but is most
readily produced by in vitro transcription using an IAP related
nucleic acids under the control of a high efficiency promoter
(e.g., the T7 promoter). Administration of IAP antisense mRNA to
malignant cells can be carried out by any of the methods for direct
nucleic acid administration described above.
[0098] Ideally, the production of IAP protein by any gene therapy
approach will result in cellular levels of and/or fragments thereof
that are at least equivalent to the normal, cellular level of IAP
in an unaffected cell. Treatment by any IAP-modulating gene therapy
approach may be combined with more traditional therapies.
[0099] Another therapeutic approach within the invention involves
administration of recombinant IAP protein fragments or IAP
antibodies, either directly to the site where enhanced apoptosis is
desirable (for example, by injection) or systemically (for example,
by any conventional recombinant protein administration
technique).
[0100] The dosage of IAP, the IAP fragment, IAP mutant protein or
IAP antibody depends on a number of factors, including the size and
health of the individual patient, but, generally, between 0.1 mg
and 100 mg inclusive are administered per day to an adult in any
pharmaceutically acceptable formulation.
Administration
[0101] An IAP mutant protein or protein fragment, a gene encoding
the same, a gene encoding an IAP antisense oligonucleotide, or
modulator of an IAP may be administered within a
pharmaceutically-acceptable diluent, carrier, or excipient, in unit
dosage form. Conventional pharmaceutical practice may be employed
to provide suitable formulations or compositions to administer the
compounds to patients suffering from a disease that is caused by
excessive cell proliferation. Administration may begin before the
patient is symptomatic. Any appropriate route of administration may
be employed, for example, administration may be parenteral,
intravenous, intraarterial, subcutaneous, intramuscular,
intracranial, intraorbital, ophthalmic, intraventricular,
intracapsular, intraspinal, intracisternal, intraperitoneal,
intranasal, aerosol, suppository, or oral administration. For
example, therapeutic formulations may be in the form of liquid
solutions or suspensions; for oral administration, formulations may
be in the form of tablets or capsules; and for intranasal
formulations, in the form of powders, nasal drops, or aerosols.
[0102] Methods well known in the art for making formulations are
found, for example, in "Remington's Pharmaceutical Sciences."
Formulations for parenteral-administration may, for example,
contain excipients-, sterile-water, or saline, polyalkylene glycols
such as polyethylene glycol, oils of vegetable origin or
hydrogenated napthalenes. Biocompatible, biodegradable lactide
polymer, lactid/glycolide copolymer, or
polyoxyethylene-polyoxypropylene copolymers may be used to control
the release of the compounds. Other potentially useful parenteral
delivery systems for IAP modulatory compounds include
ethylene-vinyl acetate copolymer particles, osmotic pumps,
implantable infusion systems, and liposomes. Formulations for
inhalation may contain excipients, for example, lactose, or may be
aqueous solutions containing, for example, polyoxyethylene-9-lauryl
ether, glycocholate and deoxycholate, or may be oily solutions for
administration in the form of nasal drops, or as a gel.
[0103] If desired, treatment with an IAP mutant proteins or IAP
fragments, related genes, or other modulatory compounds may be
combined with more traditional therapies for the proliferative
disease such as surgery or chemotherapy.
Detection of Conditions Involving Insufficient Apoptosis
[0104] IAP polypeptides and nucleic acid sequences find diagnostic
use in the detection or monitoring of conditions involving
insufficient levels of apoptosis, i.e., proliferative disease. For
example, increased expression of IAPs, altercations in
localization, and IAP cleavage correlate with inhibition of
apoptosis and cancer in humans. Accordingly, an increase in the
level of IAP production may provide an indication of a
proliferative condition or a predisposition to such a condition.
Levels of IAP expression may be assayed by any standard technique.
For example, IAP expression in a biological sample (e.g., a biopsy
sample) may be monitored by standard Northern blot analysis or may
be aided by PCR (see, e.g., Ausubel et al., supra; PCR Technology:
Principles and Applications for DNA Amplification, H. A. Ehrlich,
Ed. Stockton Press, NY; Yap et al. Nucl. Acids. Res. 19:4294,
1991).
[0105] Alternatively, a biological sample obtained from a patient
may be analyzed for one or more mutations in the IAP sequences or
p53 sequences using a mismatch detection approach. Generally, these
techniques involve PCR amplification of nucleic acid from the
patient sample, followed by identification of the mutation (i.e.,
mismatch) by either altered hybridization, aberrant electrophoretic
gel migration, binding or cleavage mediated by mismatch binding
proteins, or direct nucleic acid sequencing. Any of these
techniques may be used to facilitate mutant IAP detection, and each
is well known in the art; examples of particular techniques are
described, without limitation, in Orita et al., Proc. Natl. Acad.
Sci. USA 86:2766-2770, 1989; Sheffield et al., Proc. Natl. Acad.
Sci. USA 86:232-236, 1989).
[0106] In yet another approach, immunoassays are used to detect or
monitor IAP protein in a biological sample. IAP-specific polyclonal
or monoclonal antibodies (produced as described above) may be used
in any standard immunoassay format (e.g., ELISA, Western blot, or
RIA) to measure IAP polypeptide level or IAP levels from cancerous
control cells. These levels would be compared to wild-type IAP
levels, with a decrease in IAP production relative to a wild-type
cell indicating a condition involving increased apoptosis and a
decrease relative to a known cancer cell indicating a decreased
likelihood of an IAP related cancer. Examples of immunoassays are
described, e.g., in Ausubel et al., supra. Immunohistochemical
techniques may also be utilized for IAP detection. For example, a
tissue sample may be obtained from a patient, sectioned, and
stained for the presence of IAP using an anti-IAP antibody and any
standard detection system (e.g., one which includes a secondary
antibody conjugated to horseradish peroxidase). General guidance
regarding such techniques can be found in, e.g., Bancroft and
Stevens (Theory and Practice of Histological Techniques, Churchill
Livingstone, 1982) and Ausubel et al. (supra).
[0107] In one preferred example, a combined diagnostic method may
be employed that begins with an evaluation of IAP protein
production (for example, by immunological techniques or the protein
truncation test Hogerrorst et al., Nature Genetics 10:208-212,
1995)) and also includes a nucleic acid-based detection technique
designed to identify more subtle IAP altercations, e.g., mutations.
As described above, a number of mismatch detection assays are
available to those skilled in the art, and any preferred technique
may be used Mutations in IAP may be detected that either result in
enhanced IAP expression or altercations in IAP biological activity.
In a variation of this combined diagnostic method, IAP biological
activity is measured as anti-apoptotic activity using any
appropriate apoptosis assay system (for example, those described
above).
[0108] Mismatch detection assays also provide an opportunity to
diagnose an IAP-mediated predisposition to diseases caused by
insufficient apoptosis. For example, a patient heterozygous for an
IAP mutation may show no clinical symptoms and yet possess a higher
than normal probability of developing one or more types of
proliferative diseases. Given this diagnosis, a patient may take
precautions to minimize their exposure to adverse environmental
factors (for example, UV exposure or chemical mutagens) and to
carefully monitor their medical condition (for example, through
frequent physical examinations). This type of IAP diagnostic
approach may also be used to detect IAP mutations in prenatal
screens. The IAP diagnostic assays described above may be carried
out using any biological sample (for example, any biopsy sample or
bodily fluid or tissue) in which IAP is normally expressed.
Identification of a mutant IAP gene may also be assayed using these
sources for test samples.
[0109] Alternatively, an altercation in IAP activity, particularly
as part of a diagnosis for predisposition to IAP-associated
proliferative disease, may be tested using a nucleic acid sample
from any cell, for example, by mismatch detection techniques.
Preferably, the DNA sample is subjected to PCR amplification prior
to analysis.
EXAMPLE 1
Elevated IAP Levels in Cancer Cell Lines
[0110] In order to specifically demonstrate the utility of IAP gene
sequences as diagnostics and prognostics for cancer, a Human Cancer
Cell Line Multiple Tissue Northern Blot (Clontech, Palo Alto,
Calif.; #7757-1) was probed. This Northern blot contained
approximately 2 .mu.g of poly A+ RNA per lane from eight different
human cell lines: (1) promyelocytic leukemia HL-60, (2) HeLa cell
S3, (3) chronic myelogenous leukemia K-562, (4) lymphoblastic
leukemia MOLT-4, (5) Burkitt's lymphoma Raji, (6) colorectal
adenocarcinoma SW480, (7) lung carcinoma A549, and (8) melanoma
G361. As a control, a Human Multiple Tissue Northern Blot
(Clontech, Palo Alto, Calif.; #7759-1) was probed. This Northern
blot contained approximately 2 .mu.g of poly A+ RNA from eight
different human tissues: (1) spleen, (2) thymus, (3) prostate, (4)
testis, (5) ovary, (6) small intestine, (7) colon, and (8)
peripheral blood leukocytes.
[0111] The Northern blots were hybridized sequentially with: (1) a
1.6 kb probe to the xiap coding region, (2) a-375 bp hiap-2
specific probe corresponding to the 3' untranslated region, (3) a
1.3 kb probe to the coding region of hiap-1, which cross-reacts
with hiap-2, (4) a 1.0 kb probe derived from the coding region of
bcl-2, and (5) a probe to .beta.-actin, which was provided by the
manufacturer. Hybridization was carried out at 50.degree. C.
overnight, according to the manufacturer's suggestion. The blot was
washed twice with 2.times.SSC, 0.1% SDS at room temperature for 15
minutes and then with 2.times.SSC, 0.1% SDS at 50.degree. C.
[0112] All cancer lines tested showed increased IAP expression
relative to samples from non-cancerous control tissues (Table 1).
Expression of xiap was particularly high in HeLa (S-3), chronic
myelogenous leukemia (K-562), colorectal adenocarcinoma (SW480),
and melanoma (G-361) lines. Expression of hiap-1 was extremely high
in Burkitt's lymphoma, and was also elevated in colorectal
adenocarcinoma. Expression of hiap-2 was particularly high in
chronic myelogenous leukemia (K-562) and colorectal adenocarcinoma
(SW480). Expression of Bcl-2 was upregulated only in HL-60 leukemia
cells.
TABLE-US-00001 TABLE 1 NORTHERN BLOT IAP RNA LEVELS IN CANCER
CELLS* xiap hiap1 hiap2 Promyelocytic Leukemia HL-60 + + + HeLa S-3
+ + + Chronic Myelogenous Leukemia K-562 +++ + +++ Lymphoblastic
Leukemia MOLT-4 +++ + + Burkitt's Lymphoma Raji + +(.times.10) +
Colorectal Adenocarcinoma SW-480 +++ +++ +++ Lung Carcinoma A-549 +
+ + Melanoma G-361 +++ + + *Levels are indicated by a (+) and are
the approximate increase in RNA levels relative to Northern blots
of RNA from non-cancerous control cell lines. A single plus
indicates an estimated increase of at least 1-fold
[0113] These observations indicate that upregulation of the
anti-apoptotic IAP genes may be a widespread phenomenon in
proliferative diseases, perhaps occurring much more frequently than
upregulation of Bcl-2. Furthermore, upregulation may be necessary
for the establishment or maintenance of the transformed state of
cancerous cells.
[0114] In order to pursue the observation described above, i.e.,
that hiap-1 is overexpressed in the Raji Burkitt's lymphoma cell
line, RT-PCR analysis was performed in multiple Burkitt's lymphoma
cell lines. Total RNA was extracted from cells of the Raji, Ramos,
EB-3, and Jiyoye cell lines, and as a positive control, from normal
placental tissue. The RNA was reverse transcribed, and amplified by
PCR with the following set of oligonucleotide primers:
5'-AGTGCGGGTTTTTATTATGTG-3'(SEQ ID NO:15) and
5'-AGATGACCACAAGGAATAAACACTA-3' (SEQ ID NO:16), which selectively
amplify a hiap-1 cDNA fragment RT-PCR was conducted using a Perkin
Elmer 480 Thermocycler to carry out 35 cycles of the following
program: 94.degree. C. for 1 minute, 50.degree. C. for 1.5 minutes,
and 72.degree. C. for a minute. The PCR reaction product was
electrophoresed on an agarose gel and stained with ethidium
bromide. Amplified cDNA fragments of the appropriate size were
clearly visible all lanes containing Burkitt's lymphoma-samples,
but absent in the lanes containing the normal placental tissue
sample, and absent in lanes containing negative control samples,
where template DNA was omitted from the reaction (FIG. 11).
EXAMPLE 2
IAPs in Breast Cancer
[0115] The following data relate to the regulation and role of
HIAPs in cancer cells. FIGS. 18 and 19 show data demonstrating that
HIAP-1 and HIAP-2 are both upregulated in breast cancer cell lines
that contain mutant p53. The lanes contain 20 .mu.g of total RNA
from the following lines: 1. MCF-7(clone 1, wt p53) 2. MCF-7 (clone
2, wt p53).sub.3. MCF-7 (American Type Culture Collection, wt
p53).sub.4. MCF-7 (parental line, California, wt p53).sub.5. MCF-7
(California, adriamycin resistant variant, mutant p53), 6. MDA MB
231 (ATCC, mutant p53, codon 280).sub.7.T47-D (ATCC, mutant p53,
codon 194).sub.7. ZR-75 (ATCC, wt p53). The amount of RNA loaded on
each gel was controlled for by hybridization with glycerol
phosphate dehydrogenase (GAPDH).
EXAMPLE 3
IAPs in Ovarian Cancer
Overview
[0116] Epithelial ovarian cancer is the leading cause of death from
gynecologic malignancy. Although clinical and histologic prognostic
factors such as tumor grade and surgical stage are well understood,
the biologic process that leads to uncontrolled cellular growth is
less clear. The control of cell numbers during tissue growth is
thought to be the results of a balance of cell proliferation and
cell death. An aberration in this natural homeostasis likely
contributes to malignant cellular transformation.
[0117] Recent studies on ovarian cancer cell biology have suggested
that the deregulation of apoptosis may be one of the underlying
pathologic mechanism in this disease. However, the molecular
mechanisms involved in its regulation is poorly understood and the
role and regulation of the IAP genes in ovarian cell transformation
have not been examined previously. Ovarian epithelial cancer is in
part a result of suppressed apoptosis of ovarian surface epithelial
cells. The effectiveness of certain chemotherapeutic agents rests
on their ability to induce cell death. The loss of responsiveness
of the cells to these agents is due to a desensitization of the
apoptotic process to these agents. The regulation of ovarian
epithelial cell apoptosis involves changes in the expression of IAP
genes and post-translational modification/processing of the IAP
gene products.
[0118] We have conducted experiments and now believe that IAPs play
a key role in maintaining the normal growth of ovarian surface
epithelial cells and that the overexpression of these genes leads
to cellular transformation. Furthermore, we have discovered that
the effectiveness of chemotherapeutic agents in the treatment of
this form of malignancy rests upon their ability to suppress the
expression of the IAP genes. By seeking to control the regulation
of the IAP genes in human ovarian epithelial cancer cells we have
provided a rational approach for the development of new
chemotherapeutics for patients both responsive and resistant to
current cancer drugs. Similarly, assays designed to detect
compounds which decrease IAP biological activity provide a rational
method for drug discovery.
Methods
A) Human Ovarian Epithelial Cancer Cell Culture
[0119] Cisplatin-sensitive (OV2008) and resistant (C13) human
ovarian epithelial cells were cultured in a chemically-defined
medium at 37.degree. C. for up to 48 hours in the presence or
absence of TGF.beta. (20 ng/ml), taxol (0-1.0 .mu.M or cisplatin
(0-30 .mu.M). At the end of the culture period, cells were either
fixed for immunocytochemistry and TUNEL analyses, or snap frozen
for subsequent extraction for IAP mRNA and proteins analyses.
B) Identification of Cell Death
Nuclear Staining:
[0120] Human ovarian epithelial cancer cells were fixed (4%
formalin in PBS; 10 min. RT), washed in PBS, resuspended in Hoescht
33248 stain (0.1 .mu.g/ml PBS, 10 min) washed again and spotted
onto slides for microscopy. Nuclear staining was observed and
photographed using a Zeiss fluorescent microscope equipped with an
FITC filter. Apoptotic cells were identified by typical nuclear
morphology, and counted using randomly selected fields and numbered
photographic slides to avoid bias during counting.
Quantification of DNA Ladders:
[0121] Cellular DNA was extracted using the Qiagen Blood Amt kit.
DNA was quantified by ethidium bromide fluorescence. DNA (0.5
.mu.g) was then end labelled by incubating (20 min, RT) with Klenow
enzyme (2 U in 10 mM Tris+5 mM MgCl.sub.2) and 0.1 .mu.Ci
[.alpha.32P]dCTP. Unincorporated nucleotides were removed with the
Qiagen nucleotide removal kit and samples were resolved by
Tris-acetate-EDTA agarose-(1.8%) gel electrophoresis; The gel was
then dried (2 hr, no heat) and exposed to a Bio-Rad phosphoimager
screen to densitometrically quantify low molecular weight DNA
(<15 kBp) and subsequently to x-ray film at -80.degree. C.
In Situ TUNEL Labelling of Apoptotic Cells:
[0122] To identify cell death using the in situ cell death
detection kit (Boehringer-Mannheim), slides prepared for histology
were treated (20 min. 37.degree. C.) with terminal tranferase in
the presence of FITC-conjugated dUTP.
C) Western Blot Analyses for IAPs
[0123] Protein extracts were prepared from human surface epithelial
cancer cells sonicated (8s/cycle, 3 cycles) on ice in sucrose
buffer (0.25 M sucrose, 0.025 M NaCl, 1 mM EGTA and 15 mM Tris-HCl
pH 6.8, supplemented with 1 mM PMSF, 2 .mu.g/ml of leupeptin and 5
.mu.g/ml of aprotinin. The sonicates were centrifuged at 13,000 xg
for 10 min, the supernatants were collected and stored at
-20.degree. C. until electrophoretic analyses were performed.
Protein concentration was determined by Bio-Rad Protein Assay.
Proteins (10-30 .mu.g) were resolved by one-dimensional SDS-PAGE,
and electrophoretically transferred to nitrocellulose membrane.
Membranes were blocked with 5% non-fat milk, and subsequently
incubated with rabbit polyclonal antibody for IAP [anti-human
Hiap-2.DELTA.E(960529; 1:1000 dilution), anti-human NAIP E1.0
(951015; 1:1000 dilution) or anti-human Xiap (1:1000 dilution)
diluted in TBST (10 mM Tris-buffered saline, 0.1% Tween-20, pH 7.5)
containing 5% milk An ECL kit was used to visualize immunopositive
protein.
D) Northern Blots for IAP mRNAs
[0124] Total RNA from ovarian surface epithelial cancer cells by
using RNeasy Kit (Qiagen). The RNA samples (10-15 .mu.g) were
quantified spectrophotometrically and size-fractioned by
electrophoresis on formaldehyde-agarose gels (1.1%) containing 1
.mu.g/ml ethidium bromide to confirm even loading of RNA samples
and adequate separation of 28S and 18S ribosomal bands. The RNAs
bands were blotted onto a nylon membrane and cross-linked by UV
light. Membranes were prehybridized in 50% formamide, saline sodium
citrate (SSC; 750 mM NaCl, 75 mM Na citrate), 1.times.Denhardt's
solution, 1% SDS, 4 mM EDTA and 100 .mu.g/ml sheared salmon sperm
DNA for 4 h at 42.degree. C. Hybridization was performed overnight
at 42.degree. C. with 20 million cpm of .sup.32P-labelled IAP cDNA
probes (rat Naip, rat Xiap or human Hiap-2) added to the
prehybridization buffer. The membranes were then washed twice with
SSC (300 mM NaCl, 30 mM Na citrate) in 0.1% SDS for 20 min at room
temperature and twice with SSC (30 mM NaCl, 3 mM sodium citrate) in
0.1% SDS for 20 min at 55.degree. C. and exposed to X-ray film at
-80.degree. C. for visualization. Densitometric analysis of various
IAPs and 28S rRNA band was performed with the Image Analysis
Systems from Bio-Rad Laboratories. Data were normalized by the
respective 28S and expressed as a percentage of the control
(defined as 100%).
Results
[0125] Cisplatin induced a concentration-dependent increase in the
incidence of apoptosis in cisplatin-sensitive (OV2008) but to a
lesser extent in resistant (C 13) human ovarian epithelial cells in
vitro (FIG. 20). Similarly, Taxol also induced apoptosis in OV2008
cells, but to a lesser extent in the C13 cells (FIG. 21).
[0126] Basal XIAP and HIAP-2 protein contents were markedly higher
in cisplatin-sensitive than resistant cells. Taxol (0.04-1.0 .mu.M)
decreased XIAP and HIAP-2 protein levels in a
concentration-dependent manner, the response being more pronounced
in sensitive than resistant cells
(FIG. 22). A lower molecular weight (approx. 45 kDa) immunoreactive
fragment of HIAP-2 was also evident in both the sensitive and
resistant cells. The content of this fragment was increased in the
C13 cells but decreased in OV2008 cells by Taxol (FIG. 22).
[0127] Whereas Taxol (0.2 .mu.M) marked suppressed HIAP-2 mRNA
abundance in cisplatin-sensitive cells (approx. 80%), it was
ineffective in the resistant cells (FIG. 23).
[0128] TGF.beta. (20 ng/ml) induced apoptosis in OV2008 but not in
C13. Although its influence on Xiap protein content in
cisplatin-resistant cells was only marginal, it markedly suppressed
the protein level of this IAP in the cisplatin-sensitive cells
(FIG. 24A, 24B). TGF.beta. (20 ng/ml) also decreased HIAP-2 mRNA in
OV2008 but not C13 cells (FIG. 23).
Significant Observations and Possible Applications
[0129] Induction of apoptosis in human ovarian epithelial cancer
cell by taxol was accompanied by suppressed IAP gene expression.
The lost of sensitivity of the cells to the chemotherapeutic agent
may be associated with its decreased ability to express these genes
and to induce apoptosis. In drug-resistant cells, the decreased
Hiap-2 protein content (in the face of an absence of noticeable
change in Hiap-2 mRNA abundance) in the presence of Taxol was
accompanied an increase in the intensity of a 4 kDa immunoreactive
HIAP-2 protein band. These observations lead us to believe that the
45 kDa protein is a proteolytic product of HIAP-2 and plays a role
in the development of drug resistance. In addition, the sensitivity
of the IAP family in these ovarian cancer cells to Taxol suggest
possible novel sites for gene targeting in the development of new
chemotherapeutic agents for the treatment of human ovarian
epithelial cell cancer.
EXAMPLE 4
Accumulation of a 26 kDa Cleavage Protein in Astrocytoma Cells
Identification of a 26 kDa Cleavage Protein
[0130] A total protein extract was prepared from Jurkat and
astrocytoma cells by sonicating them (.times.3 for 15 seconds at
4.degree. C.) in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl 1 mM PMSF, 1
.mu.g/ml aprotinin, and 5 mM benzamidine. Following sonication, the
samples were centrifuged (14,000 RPM in a microfuge) for five
minutes. Twenty .mu.g of protein was loaded per well on a 10%
SDS-polyacrylamide gel, electrophoresed, and electroblotted by
standard methods to PVDF membranes. Western blot analysis,
performed as described previously, revealed that the astrocytoma
cell line (CCF-STTG1) abundantly expressed an anti-xiap reactive
band of approximately 26 kDa, despite the lack of an apoptotic
trigger event (FIG. 12). In fact, this cell line has been
previously characterized as being particularly resistant to
standard apoptotic triggers.
[0131] A 26 kDa xiap-reactive band was also observed under the
following experimental conditions. Jurkat cells (a transformed
human T cell line) were induced to undergo apoptosis by exposure to
an anti-Fas antibody (1 .mu.g/ml). Identical cultures of Jurkat
cells were exposed either to: (1) anti-Fas antibody and
cycloheximide (20 .mu.g/ml), (2) tumor necrosis factor alpha
(TNF-.alpha., at 1,000 U/ml), or (3) TNF-.alpha. and cycloheximide
(20 .mu.g/ml). All cells were harvested 6 hours after treatment
began. In addition, as a negative control, anti-Fas antibody was
added to an extract after the cells were harvested. The cells were
harvested in SDS sample buffer, electrophoresed on a 12.5% SDS
polyacrylamide gel, and electroblotted onto PVDF membranes using
standard methods. The membranes were immunostained with a rabbit
polyclonal anti-xiap antibody at 1:1000 for 1 hour at room
temperature. Following four 15 minute washes, a goat anti-rabbit
antibody conjugated to horse-radish peroxidase was applied at room
temperature for 1 hour. Unbound secondary antibody was washed away,
and chemiluminescent detection of xiap protein was performed The
Western blot revealed the presence of the full-length, 55 kDa xiap
protein, both in untreated and treated cells. In addition, a novel,
approximately 26 kDa xiap-reactive band was also observed in
apoptotic cell extracts, but not in the control, untreated cell
extracts (FIG. 13).
[0132] Cleavage of xiap occurs in a variety of cell types,
including other cancer cell fines such as HeLa. The expression of
the 26 kDa xiap cleavage product was demonstrated in HeLa cells as
follows. HeLa cells were treated with either: (1) cyclohexamide (20
.mu.g/ml), (2) anti-Fas antibody (1 .mu.g/ml), (3) anti-Fas
antibody (1 .mu.g/ml) and cyclohexamide (20 .mu.g/ml), (4)
TNF.alpha. (1,000 U/ml), or (5) TNF.alpha. (1,000 U/ml) and
cyclohexamide (20 .mu.g/ml). All cells were harvested 18 hours
after treatment began. As above, anti-Fas antibody was added to an
extract after the cells were harvested. HeLa cells were harvested,
and the Western blot was probed under the same conditions as used
to visualize xiap-reactive bands from Jurkat cell samples. A 26 kDa
xiap band was again seen in the apoptotic cell preparations (FIG.
14). Furthermore, the degree of xiap cleavage correlated positively
with cellular exposure to apoptotic triggers. Treatment of HeLa
cells with cycloheximide or TNF.alpha. alone caused only minor
apoptosis, and little cleavage product was observed. If the cells
were treated with the anti-Fas antibody, a greater amount of
cleavage product was apparent. These data indicate that xiap is
cleaved in more than one cell type and in response to more than one
type of apoptotic trigger.
Time Course of Expression
[0133] The time course over which the 26 kDa cleavage product
accumulates was examined by treating HeLa and Jurkat cells with
anti-Fas antibody (1 .mu.g/ml) and harvesting them either
immediately, or 1, 2, 3, 5, 10, or 22 hours after treatment.
Protein extracts were prepared and Western blot analysis was
performed as described above. Both types of cells accumulated
increasing quantities of the 26 kDa cleavage product over the time
course examined (FIGS. 15A and 15B).
Subcellular Localization of the 26 kDa xiap Cleavage Product
[0134] In order to determine the subcellular location of the 26 kDa
cleavage product, Jurkat cells were induced to undergo apoptosis by
exposure to anti-Fas antibody (1 .mu.g/ml) and were then harvested
either immediately, 3 hours, or 7 hours later. Total protein
extracts were prepared, as described above, from cells harvested at
each time point. In order to prepare nuclear and cytoplasmic cell
extracts, apoptotic Jurkat cells were washed with isotonic Tris
buffered saline (pH 7.0) and lysed by freezing and thawing five
times in cell extraction buffer (50 mM PIPES, 5 mM KCl, 5 mM EGTA,
2 mM MgCl.sub.2, 1 mM DTT, and 20 .mu.M cytochalasin B). Nuclei
were pelleted by centrifugation and resuspended in isotonic Tris
(pH 7.0) and frozen at -80.degree. C. The cytoplasmic fraction of
the extract was processed further by centrifugation at 60,000 RPM
in a TA 100.3 rotor for 30 minutes. Supernatants were removed and
frozen at -80.degree. C. Samples of both nuclear and cytoplasmic
fractions were loaded on a 12.5% SDS-polyacrylamide gel, and
electroblotted onto PVDF membranes. Western blot analysis was then
performed using either an anti-CPP32 antibody (Transduction
Laboratories Lexington, Ky.; FIG. 16A) or the rabbit anti-XIAP
antibody described above (FIG. 16B).
[0135] The anti-CPP32 antibody, which recognizes the CPP32 protease
(also known as YAMA or Apopain) partitioned almost exclusively in
the cytoplasmic fraction. The 55 kDa XIAP protein localized
exclusively in the cytoplasm of apoptotic cells, in agreement with
the studies presented above, where XIAP protein in normal, healthy
COS cells was seen to localize, by immunofluorescence microscopy,
to the cytoplasm. In contrast, the 26 kDa cleavage product
localized exclusively to the nuclear fraction of apoptotic Jurkat
cells. Taken together, these observations suggest that the
anti-apoptotic component of XIAP could be the 26 kDa cleavage
product, which exerts its influence within the nucleus.
In vitro Cleavage of xiap Protein and Characterization of the
Cleavage Product
[0136] For this series of experiments, xiap protein was labeled
with .sup.35S using the plasmid pCDNA3-6myc-XIAP, T7 RNA
polymerase, and a coupled transcription/translation kit (Promega)
according to the manufacturer's instructions. Radioactively labeled
xiap protein was separated from unincorporated methionine by column
chromatography using Sephadex G-50.TM.. In addition, extracts of
apoptotic Jurkat cells were prepared following treatment with
anti-Fas antibody (1 .mu.g/ml) for three hours. To prepare the
extracts, the cells were lysed in Triton X-100 buffer (1% Triton
X-100, 25 mM Tris HCl) on ice for two hours and then
microcentrifuged for 5 minutes. The soluble extract was retained
(and was labeled TX100). Cells were lysed in cell extraction buffer
with freeze/thawing. The soluble cytoplasmic fraction was set aside
(and labeled CEB). Nuclear pellets from the preparation of the CEB
cytoplasmic fraction were solubilized with Triton X-100 buffer,
microcentrifuged, and the soluble fractions, which contains
primarily nuclear DNA, was retained (and labeled CEB-TX100).
Soluble cell extract was prepared by lysing cells with NP-40
buffer, followed by microcentrifugation for 5 minutes (and was
labeled NP-40). In vitro cleavage was performed by incubating 16
.mu.l of each extract (CEB, TX-100, CEB-TX100, and NP40) with 4
.mu.L of in vitro translated XIAP protein at 37.degree. C. for 7
hours. Negative controls, containing only TX100 buffer or CEB
buffer were also included. The proteins were separated on a 10%
SDS-polyacrylamide gel, which was dried and exposed to X-ray film
overnight.
[0137] In vitro cleavage of XIAP was apparent in the CEB extract.
The observed molecular weight of the cleavage product was
approximately 36 kDa (FIG. 17). The 10 kDa shift in the size of the
cleavage product indicates that the observed product is derived
from the amino-terminus of the recombinant protein, which contains
six copies of the myc epitope (10 kDa). It thus appears that the
cleavage product possesses at least two of the BIR domains, and
that it is localized to the nucleus.
EXAMPLE 5
Characterization of IAP-Activity and Intracellular Localization
Studies
[0138] The ability of IAPs to modulate apoptosis can be defined in
vitro systems in which alterations of apoptosis can be detected.
Mammalian expression constructs carrying IAP cDNAs, which are
either full-length truncated, or antisense constructs can be
introduced into cell lines such as CHO, NIH 3T3, HL60, Rat-1, or
Jurkat cells. In addition, SF21 insect cells may be used, in which
case the IAP gene is preferentially expressed using an insect heat
shock promoter. Following transfection, apoptosis can be induced by
standard methods, which include serum withdrawal, or application of
staurosporine, menadione (which induces apoptosis via free radial
formation), or anti-Fas antibodies. As a control, cells are
cultured under the same conditions as those induced to undergo
apoptosis, but either not transfected, or transfected with a vector
that lacks an IAP insert The ability of each IAP related construct
to inhibit or enhance apoptosis upon expression can be quantified
by calculating the survival index of the cells, i.e., the ratio of
surviving transfected cells to surviving control cells. These
experiments can confirm the presence of apoptosis inhibiting
activity and, as discussed below, can also be used to determine the
functional region(s) of an IAP which may be employed to achieve
enhancement of apoptosis. These assays may also be performed in
combination with the application of additional compounds in order
to identify compounds that enhance apoptosis via IAP
expression.
EXAMPLES 6
Cell Survival Following Transfection with IAP Constructs and
Induction of Apoptosis
[0139] Specific examples of the results obtained by performing
various apoptosis suppression assays are shown in FIGS. 10A to 10D.
For example, CHO cell survival following transfection with one of
six constructs and subsequent serum withdrawal is shown in FIG.
10A. The cells were transfected using Lipofectace.TM. with 2 .mu.g
of one of the following recombinant plasmids: pCDNA3-6myc-xiap
(xiap), pCDNA3-6myc-hiap-1 (hiap-1), pCDNA3-6myc-hiap-2 (hiap-2),
pCDNA3-bcl-2 (bcl-2), pCDNA3-HA-smn (smn), and pCDNA3-6myc (6-myc).
Oligonucleotide primers were synthesized to allow PCR amplification
and cloning of the xiap, hiap-1, and hiap-2 ORFs in pCDNA3
(Invitrogen). Each construct was modified to incorporate a
synthetic myc tag encoding six repeats of the peptide sequence
MEQKLISEEDL (SEQ ID NO:17), thus allowing detection of myc-IAP
fusion proteins via monoclonal anti-myc antiserun (Egan et al.,
Nature 363:45-51, 1993). Triplicate samples of cell lines in
24-well dishes were washed 5 times with serum free media and
maintained in serum free conditions during the course of the
experiment. Cells that excluded trypan blue, and that were
therefore viable, were counted with a hemocytometer immediately, 24
hours, 48 hours, and 72 hours, after serum withdrawal. Survival was
calculated as a percentage of the initial number of viable cells.
In this experiment and those presented in FIGS. 10B and 10D, the
percentage of viable cells shown represents the average of three
separate experiments performed in triplicate, +/-average
deviation.
[0140] The survival of CHO cells following transfection (with each
one of the six constructs described above) and exposure to
menadione is shown in FIG. 110B. The cells were plated in 24-well
dishes, allowed to grow overnight, and then exposed to 20 .mu.M
menadione for 1.5 hours (Sigma Chemical Co., St. Louis, Mo.).
Triplicate samples were harvested at the time of exposure to
menadione and 24 hours afterward, and survival was assessed by
trypan blue exclusion.
[0141] The survival of Rat-1 cells following transfection (with
each one of the six constructs described above) and exposure to
staurosporine is shown in FIG. 10C. Rat-1 cells were transfected
and then selected in medium containing 800 .mu.g/ml G418 for two
weeks. The cell line was assessed for resistance to
staurosporine-induced apoptosis (1 .mu.M) for 5 hours. Viable cells
were counted 24 hours after exposure to staurosporine by trypan
blue exclusion. The percentage of viable cells shown represents the
average of two experiments, .+-.average deviation.
[0142] The Rat-1 cell line was also used to test the resistance of
these cells to menadione (FIG. 10D) following transfection with
each of the six constructs described above. The cells were exposed
to 10 .mu.M menadione for 1.5 hours, and the NUMBER of viable cells
was counted 18 hours later.
EXAMPLE 7
Comparison of Cell Survival Following Transfection with Full-length
vs. Patial IAP Constructs
[0143] In order to investigate the mechanism whereby human IAPs,
including XIAP, HIAP-1, and HAP-2, afford protection against cell
death, expression vectors were constructed that contained either:
(1) full-length IAP cDNA (as described above), (2) a portion of an
IAP gene that encodes the BIR domains, but not the RZF, or (3) a
portion of an IAP gene that encodes the RZF, but not the BIR
domains. Human and murine xiap cDNAs were tested by transient or
stable expression in HeLa, Jurkat, and CHO cell lines. Following
transfection, apoptosis was induced by serum withdrawal,
application of menadione, or application of an anti-Fas antibody.
Cell death was then assessed, as described above, by trypan blue
exclusion. As a control for transfection efficiency, the cells were
co-transfected with a .beta.-gal expression construct Typically,
approximately 20% of the cells were successfully transfected.
[0144] When CHO cells were transiently transfected, constructs
containing full-length human or mouse xiap cDNAs conferred modest
but definite protection against cell death. In contrast, the
survival of CHO cells transfected with constructs encoding only the
BIR domains (i.e., lacking the RZF domain) was markedly enhanced 72
hours after serum deprivation. Furthermore, a large percentage of
cells expressing the BIR domains were still viable after 96 hours,
at which time no viable cells remained in the control, i.e.,
non-transfected, cell cultures, and less than 5% of the cells
transfected with the vector only, i.e., lacking a cDNA insert,
remained viable. Deletion of any of the BIR domains results in the
complete loss of apoptotic suppression, which is reflected by a
decrease in the percentage of surviving CHO cells to control levels
within 72 hours of serum withdrawal.
[0145] Stable pools of transfected CHO cells, which were maintained
for several months under G418 selection, were induced to undergo
apoptosis by exposure to 10 .mu.M menadione for 2 hours. Among the
CHO cells tested were those that were stably transfected with: (1)
full-length murine xiap cDNA (miap), (2) full-length xiap cDNA
(xiap), (3) full-length bcl-2 cDNA (Bcl-2), (4) cDNA encoding the
three BIR domains (but not the RZF) of murine xiap (BIR), and (5)
cDNA encoding the RZF (but not BIR domains) of m-xiap (RZF). Cells
that were non-transfected (CHO) or transfected with the vector only
(pCDNA3), served as controls for this experiments Following
exposure to 10 .mu.M menadione, the transfected cells were washed
with phosphate buffered saline (PBS) and cultured for an additional
24 hours in menadione-free medium. Cell death was assessed, as
described above, by trypan blue exclusion. Less than 10% of the
non-transfected or vector-only transfected cells remained viable at
the end of the 24 hour survival period. Cells expressing the RZF
did not fare significantly better. However, expression of
full-length murine xiap, human xiap, or bcl-2, and expression of
the BIR domains, enhanced cell survival. When the concentration of
menadione was increased from 10 .mu.M to 20 .mu.M (with all other
conditions of the experiment being the same as when 10 .mu.M
menadione was applied), the percentage of viable CHO cells that
expressed the BIR domain cDNA construct was higher than the
percentage of viable cells that expressed either fill-length murine
xiap or bcl-2.
EXAMPLE 8
Analysis of the Subcellular Location of Expressed RZF and BIR
Domains
[0146] The assays of cell death described above indicate that the
RZF acts as a negative regulator of the anti-apoptotic function of
IAPs. One way in which the RZF, and possibly other IAP domains, may
exert their regulatory influence is by altering the expression of
genes, whose products function in the apoptotic pathway.
[0147] In order to determine whether the subcellular locations of
expressed RZF and BIR domains are consistent with roles as nuclear
regulatory factors, COS 10 cells were transiently transfected with
the following four constructs, and the expressed polypeptide was
localized by immunofluorescent microscopy: (1) pCDNA3-6myc-xiap,
which encodes all 497 amino acids of SEQ ID NO:4, (2)
pCDNA3-6myc-m-xiap, which encodes all 497 amino acids of mouse xiap
(SEQ ID NO:10), (3) pCDNA3-6myc-mxiap-BIR, which encodes amino
acids 1 to 341 of m-xiap (SEQ ID NO:10), and (4)
pCDNA3-6myc-mxiap-RZF, which encodes amino acids 342497 of murine
xiap (SEQ ID NO:10). The cells were grown on multi-well tissue
culture slides for 12 hours, and then fixed and permeabilized with
methanol. The constructs used (here and in the cell death assays)
were tagged with a human Myc epitope tag at the N-terminus.
Therefore, a monoclonal anti-Myc antibody and a secondary goat
anti-mouse antibody, which was conjugated to FITC, could be used to
localize the expressed products in transiently transfected COS
cells. Full-length XIAP and MIAP were located in the cytoplasm,
with accentuated expression in the peri-nuclear zone. The same
pattern of localization was observed when the cells expressed a
construct encoding the RZF domain (but not the BIR domains).
However, cells expressing the BIR domains (without the RZF)
exhibited, primarily, nuclear staining. The protein expressed by
the BIR domain construct appeared to be in various stages of
transfer to the nucleus.
[0148] These observations are consistent with the fact that, as
described below, XIAP is cleaved within T cells that are treated
with anti-Fas antibodies (which are potent inducers of apoptosis),
and its N-terminal domain is translocated to the nucleus. As noted
in Example 2 Hiap-2 appears to undergo a similar cleavage
event.
EXAMPLE 9
Testing of Antisense Oligonucleotides
[0149] 1. Complete panel of adenovirus constructs. The panel may
consist of approximately four types of recombinant virus. A) Sense
orientation viruses for each of the IAP open reading frames. These
viruses are designed to massively overexpress the recombinant
protein in infected cells. XIAP, HIAP-1, HIAP-2, and NAIP. B)
Antisense orientation viruses in which the viral promoter drives
the synthesis of an mRNA of opposite polarity to the iap mRNA,
thereby shutting off host cell synthesis of the targeted protein
coding region. XIAP, HIAP-1, HIAP-2, and NAIP "antisense"
constructs required. C) Sub-domain expression viruses. These
constructs express only a partial IAP protein in infected cells. We
have data indicating that deletion of the zinc finger of XIAP
renders the protein more potent in protecting cell against
apoptotic triggers. This data also indicates that expression of the
zinc finger alone will indicate apoptosis by functioning as a
dominant-negative repressor of XIAP function. XIAP-.DELTA.ZF and
XIAP-.DELTA.bir viruses required. D) Control viruses. Functional
analysis of the IAPs requires suitable positive and negative
controls for comparison. Bcl-2 sense, Bcl-2 antisense, p53 sense,
and Lac Z (negative control) viruses may be utilized. 2.
Confirmation of recombinant adenovirus function. Verification of
the sense adenovirus function involves infection of tissue culture
cells and determination of protein expression levels. We have
performed western blot analysis of several of the recombinant
adenoviruses, including NAIP, XIAP and XIAP-.DELTA.ZF. The
remaining viruses may be ready readily assessed for protein
expression using the polyclonal IAP antibodies. Functional analysis
of the antisense viruses may be done at the RNA level using either
northern blots of total RNA harvested from infected tissue culture
cells or ribonuclease protection assays. Western blot analysis of
infected cells will be used to determine whether the expressed
antisense oligonucleotide interferes with IAP expression in the
host cell. 3. Documentation that IAP overexpression results in
increased drug resistance. We have optimized cell death assays to
allow high through-put of samples with minimal sample variation.
Testing of the sense IAP adenoviruses for their ability to alter
drug sensitivity of breast and pancreatic adenocarcinoma cell lines
may be accomplished as follows. Cancer cell lines are infected with
the recombinant viruses, cultured for 5 days, then subdivided into
24 well plates. Triplicate cell receive increasing concentrations
of the anti-cancer drug under investigation. Samples are harvested
at 24, 48, and 72 hours post exposure, and assayed for the number
of viable cells in the well. The dose response curve is then
compared to uninfected and control virus (both positive and
negative) infected cells. One may document a dramatic increase in
the relative resistance of the cancer cell lines when infected with
the sense viruses, confirming our hypothesis that overexpression of
the IAP proteins contributes to the anti-apoptotic phenotype of
cancer cells. Initial experiments utilize the drugs doxorubicin,
and adriamycin. 4. Documentation that antisense P overexpression
results in increased drug sensitivity. Having confirmed that IAP
overexpression renders cancer cell more resistant to
chemotherapeutic drugs, one may examine whether the antisense
adenoviruses render the same cells more sensitive. The
effectiveness of antisense IAP viruses relative to antisense Bcl-2
virus will also be assessed as a crucial milestone. 5.
Identification of antisense oligonucleotides. Concomitant to the
adenovirus work, we have designed a series of antisense
oligonucleotides to various regions of each of the iaps. A
generally accepted model of how antisense oligonucleotides function
proposes that the formation of RNA/DNA duplexes in the nucleus
activates cellular RnaseH enzymes which then enzymatically degrade
the mRNA component of the hybrid. Virtually any region of the mRNA
can be targeted, and therefore choosing an appropriate sequence to
target is somewhat empirical. Many factors, including secondary
structure of the target mRNA and the binding affinity of the
targeted sequence determine whether a particular oligonucleotide
will be effective, necessitating several oligos for each lap. Five
oligonucleotides have been made for each iap mRNA based on the
available computer algorhythms for predicting binding affinities
and mRNA secondary structures. These and other oligos may be tested
for their ability to target their respective mRNAs for degradation
using northern blot analysis. 6. Optimization of oligonucleotides.
A secondary round of oligonucleotides may be made when effective
target regions have been identified. These oligonucleotides target
sequences in the immediate vicinity of the most active antisense
oligonucleotides identified using methods such as those provided
above. A second round of testing by northern blot analysis may be
required. 7. Testing antisense oligonucleotides in vitro. Following
successful identification and optimization of targeting
oligonucleotides, one may test these in the tissue culture model
system using the optimal cell lines such as those described in the
cancer survey described herein. Experimental procedures may
parallel those used in the recombinant antisense adenovirus work.
Negative control oligonucleotides with miss-match sequences are
used to establish base line or non-specific effects. Assisted
transfection of the oligonucleotides using cationic lipid carriers
may be is compared to unassisted transfection. Confirmation of the
effectiveness of specific antisense oligonucleotides prompts
synthesis of oligos with modified phosphodiester linkages, such as
phosphorothioate or methylimino substituted oligos. These may also
be tested in vitro. 8. Animal modeling of antisense oligonucleotide
therapies. Animal modeling of the effectiveness of the antisense
IAP approach is described here. Cell lines are routinely assessed
for their tumorigenic potential in "nude" mice, a hairless strain
of mouse that is immunocompromised, and thus extremely susceptible
to developing tumors. In the nude mouse assay, cancer cells are
grown in tissue culture and then injected under the skin at
multiple sites. The frequency with which these cells give rise to
palpable tumors within a defined period of time provides an index
of the tumorigenic potential of the cell line in the absence of
interference by a functional immune system. Preliminary assessment
of an antisense IAP therapeutic involves injection of cancer cells
infected with the recombinant adenoviruses (sense, antisense, and
control viruses) under the skin, and the tumorigenic index compared
to that of untreated cells. One may also use this model to assess
the effectiveness of systemic administration of antisense
oligonucleotides in increasing the efficacy of anti-cancer drugs in
the nude mouse model. Phosphorothioate or methylimino substituted
oligos will be assessed at this stage. This type of antisense oligo
has demonstrated enhanced cell permeability and slower clearance
rates from the body in experimental animal models.
EXAMPLE 10
Additional Apoptosis Assays
[0150] Specific examples of apoptosis assays are also provided in
the following references. Assays for apoptosis in lymphocytes are
disclosed by: Li et al., "Induction of apoptosis in uninfected
lymphocytes by HIV-1 Tat protein", Science 268:429-431, 1995;
Gibellini et al., "Tat-expressing Jurkat cells show an increased
resistance to different apoptotic stimuli, including acute human
immunodeficiency virus-type 1 (HIV-1) infection", Br. J. Haematol.
89:24-33, 1995; Martin et al., "HIV-1 infection of human CD 4.sup.+
T cells in vitro. Differential induction of apoptosis in these
cells." J. Immunol. 152:330-42, 1994; Terai et al., "Apoptosis as a
mechanism of cell death in cultured T lymphoblasts acutely infected
with HIV-1", J. Clin. Invest. 87:1710-5, 1991; Dhein et al.,
"Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)11, Nature
373:438-441, 1995; Katsikis et al., "Fas antigen stimulation
induces marked apoptosis of T lymphocytes in human immunodeficiency
virus-infected individuals", J. Exp. Med. 1815:2029-2036, 1995;
Westendorp et al., Sensitization of T cells to CD95-mediated
apoptosis by HIV-1 Tat and gp12O", Nature 375:497, 1995; DeRossi et
al., Virology 198:23444, 1994.
[0151] Assays for apoptosis in fibroblasts are disclosed by:
Vossbeck et al., "Direct transforming activity of TGF-beta on rat
fibroblasts", Int. J. Cancer 61:92-97, 1995; Goruppi et al.,
"Dissection of c-myc domains involved in S phase induction of
NIH3T3fibroblasts", Oncogene 9:1537-44, 1994, Fernandez et al.,
"Differential sensitivity of normal and Ha-ras transformed C3H
mouse embryo fibroblasts to tumor necrosis factor: induction of
bcl-2, c-myc, and manganese superoxide dismutase in resistant
cells", Oncogene 9:2009-17, 1994; Harrington et al., "c-Myc-induced
apoptosis in fibroblasts is inhibited by specific cytokines", EMBO
J., 13:3286-3295, 1994; Itoh et al., "A novel protein domain
required for apoptosis. Mutational analysis of human Fas antigen",
J. Biol. Chem. 268:10932-7, 1993.
[0152] Assays for apoptosis in neuronal cells are disclosed by:
Melino et al., "Tissue transglutaminase and apoptosis: sense and
antisense transfection studies with human neuroblastoma cells",
Mol. Cell. Biol. 14:6584-6596, 1994; Rosenbaum et al., "Evidence
for hypoxia-induced, programmed cell death of cultured neurons",
Ann. Neurol. 36:864-870, 1994; Sato et al., "Neuronal
differentiation of PC12 cells as a result of prevention of cell
death by bcl-2", J. Neurobiol. 25:1227-1234, 1994; Ferrari et al.,
"N-acetylcysteine D- and L-stereoisomers prevents apoptotic death
of neuronal cells", J. Neurosci. 1516:2857-2866, 1995; Talley et
al., "Tumor necrosis factor alpha-induced apoptosis in human
neuronal cells: protection by the antioxidant N-acetylcysteine and
the genes bcl-2 and crmA", Mol. Cell. Biol. 1585:2359-2366, 1995;
Talley et al., "Tumor Necrosis Factor Alpha-Induced Apoptosis in
Human Neuronal Cells: Protection by the Antioxidant NAcetylcysteine
and the Genes bcl-2 and crma", Mol. Cell. Biol. 15:2359-2366, 1995;
Walkinshaw et al., "Induction of apoptosis in catecholaminergic
PC12 cells by L-DOPA. Implications for the treatment of Parkinson's
disease.", J. Clin. Invest. 95:2458-2464, 1995.
[0153] Assays for apoptosis in insect cells are disclosed by: Clem
et al., "Prevention of apoptosis by a baculovirus gene during
infection of insect cells", Science 254:1388-90, 1991; Crook et
al., "An apoptosis-inhibiting baculovirus gene with a zinc
finger-like motif", J. Virol. 67:2168-74, 1993; Rabizadeh et al.,
"Expression of the baculovirus p35 gene inhibits mammalian neural
cell death", 15J. Neurochem. 61:2318-21, 1993; Birnbaum et al., "An
apoptosis inhibiting gene from a nuclear polyhedrosis-virus
encoding a polypeptide with Cys/His sequence motifs", J. Virol.
68:2521-8, 1994; Clem et al., "Control of programmed cell death by
the baculovirus genes p35 and IAP", Mol. Cell. Biol. 14:5212-5222,
1994.
EXAMPLE 11
Construction of a Transgenic Animal
[0154] Characterization of IAP genes provided information that
necessary for generation IAP transgenic animal models to be
developed by homologous recombination (for knockouts) or
transfection (for expression of IAP fragments, antisense IAP
oligonucleotides, or increased expression of wild-type or mutant
IAPs). Such models may be mammalian animal, e.g., a mouse. Such
models are useful for the identification of cancer therapeutics
alone or in combination with cancer inducing cells or agents, or
when such mice are crossed with mice genetically predisposed to
cancers.
[0155] The preferred transgenic animal overexpression in IAP and
has a predisposition to cancer. This mouse is particularly useful
for the screening of potential cancer therapeutics.
EXAMPLE 12
IAP Protein Expression
[0156] IAP genes and fragments thereof (i.e., RZF fragments) may be
expressed in both prokaryotic and eukaryotic cell types. If an IAP
fragment modulates apoptosis by exacerbating it, it may be
desirable to express that protein under control of an inducible
promoter.
[0157] In general, IAPs and fragments thereof may be produced by
transforming a suitable host cell with all or part of the
IAP-encoding cDNA fragment that has been placed into a suitable
expression vector.
[0158] Those skilled in the art of molecular biology will
understand that a wide variety of expression systems may be used to
produce the recombinant protein. The precise host cell used is not
critical to the invention, although cancer cells are preferable.
The IAP protein may be produced in a prokaryotic host (e.g., E.
coli) or in a eukaryotic host (e.g., S. cerevisiae, insect cells
such as Sf21 cells, or mammalian cells such as COS-1, NIH 3T3, or
HeLa cells, or other highly proliferative cell types). These cells
are publically available, for example, from the American Type
Culture Collection, Rockville, Md.; see also Ausubel et al.,
Current Protocols in Molecular Biology, John Wiley & Sons, New
York, N.Y., 1994). The method of transduction and the choice of
expression vehicle will depend on the host system selected.
Transformation and transfection methods are described, e.g., in
Ausubel et al. (supra), and expression vehicles may be chosen from
those provided, e.g., in Cloning Vectors: A Laboratory Manual (P.
H. Pouwels et al., 1985, Supp. 1987).
[0159] Polypeptides of the invention, particularly short IAP
fragments, can also be produced by chemical synthesis (e.g., by the
methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984
The Pierce Chemical Co., Rockford, Ill.). These general techniques
of polypeptide expression and purification can also be used to
produce and isolate useful IAP fragments or analogs, as described
herein.
EXAMPLE 13
Anti-IAP Antibodies
[0160] In order to generate IAP-specific antibodies, an IAP coding
sequence (e.g., amino acids 180-276) can be expressed as a
C-terminal fusion with glutathione S-transferase (GST; Smith et
al., Gene 67:3140, 1988). The fusion protein can be purified on
glutathione-Sepharose beads, eluted with glutathione, and cleaved
with thrombin (at the engineered cleavage site), and purified to
the degree required to successfully immunize rabbits. Primary
immunizations can be carried out with Freund's complete adjuvant
and subsequent immunizations performed with Freund's incomplete
adjuvant. Antibody titres are monitored by Western blot and
immunoprecipitation analyses using the thrombin-cleaved IAP
fragment of the GST-IAP fusion protein. Immune sera are affinity
purified using CNBr-Sepharose-coupled IAP protein. Antiserum
specificity is determined using a panel of unrelated GST proteins
(including GSTp53, Rb, HPV-16 E6, and E6-AP) and GST-trypsin (which
was generated by PCR using known sequences).
[0161] As an alternate or adjunct immunogen to GST fusion proteins,
peptides corresponding to relatively unique hydrophilic regions of
IAP may be generated and coupled to keyhole limpet hemocyanin (KLH)
through an introduced C-terminal lysine. Antiserum to each of these
peptides is similarly affinity purified on peptides conjugated to
BSA, and specificity is tested by ELISA and Western blotting using
peptide conjugates, and by Western blotting and immunoprecipitation
using IAP expressed as a GST fusion protein.
[0162] Alternatively, monoclonal antibodies may be prepared using
the IAP proteins described above and standard hybridoma technology
(see, e.g., Kohler et al., Nature 256:495, 1975; Kohler et al.,
Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J. Immunol.
6.292, 1976;Hammerling et al., In Monoclonal Antibodies and T Cell
Hybridomas, Elsevier, New York, N.Y., 1981; Ausubel et al., supra).
Once produced, monoclonal antibodies are also tested for specific
IAP recognition by Western blot or immunoprecipitation analysis (by
the methods described in Ausubel et al., supra).
[0163] Antibodies that specifically recognize IAPs or fragments of
IAPs, such as those described herein containing one or more BIR
domains (but not a ring zinc finger domain), or that contain a ring
zinc finger domain (but not a BIR domain) are considered useful in
the invention. They may, for example, be used in an immunoassay to
monitor IAP expression levels or to determine the subcellular
location of an IAP or IAP fragment produced by a mammal. Antibodies
that inhibit the 26 kDa IAP cleavage product described herein
(which contains at least one BIR domain) may be especially useful
in inducing apoptosis in cells undergoing undesirable
proliferation.
[0164] Preferably, antibodies of the invention are produced using
IAP sequence that does not reside within highly conserved regions,
and that appears likely to be antigenic, as analyzed by criteria
such as those provided by the Peptide structure program (Genetics
Computer Group Sequence Analysis Package, Program Manual for the
GCG Package, Version 7, 1991) using the algorithm of Jameson and
Wolf (CABIOS 4:181, 1988). Specifically, these regions, which are
found between BIR1 and BIR2 of all IAPs, are: from amino acid 99 to
amino acid 170 of hiap-1, from amino acid 123 to amino acid 184 of
hiap-2, and from amino acid 116 to amino acid 133 of either xiap or
m-xiap. These fragments can be generated by standard techniques,
e.g., by the PCR, and cloned into the pGEX expression vector
(Ausubel et al., supra). Fusion proteins are expressed in E. coli
and purified using a glutathione agarose affinity matrix as
described in Ausubel et al. (supra). In order to minimize the
potential for obtaining antisera that is non-specific, or exhibits
low-affinity binding to IAP, two or three fusions are generated for
each protein, and each fusion is injected into at least two
rabbits. Antisera are raised by injections in series, preferably
including at least three booster injections.
EXAMPLE 14
Identification of Molecules That Modulate IAP Protein
Expression
[0165] IAP cDNAs facilitate the identification of molecules that
decrease IAP expression or otherwise enhance apoptosis normally
blocked by the IAPs. In one approach, candidate molecules are
added, in varying concentration, to the culture medium of cells
expressing IAP mRNA. IAP expression is then measured, for example,
by Northern blot analysis (Ausubel et al., supra) using an IAP
cDNA, or cDNA fragment, as a hybridization probe. The level of IAP
expression in the presence of the candidate molecule is compared to
the level of IAP expression in the absence of the candidate
molecule, all other factors (e.g., cell type and culture
conditions) being equal.
[0166] The effect of candidate molecules on IAP-mediated apoptosis
may, instead, be measured at the level of IAP protein or level of
IAP fragments using the general approach described above with
standard protein detection techniques, such as Western blotting or
immunoprecipitation with an IAP-specific antibody (for example, the
IAP antibodies described herein).
[0167] Compounds that modulate the level of IAP may be purified, or
substantially purified, or may be one component of a mixture of
compounds such as an extract or supernatant obtained from cells
(Ausubel et al., supra). In an assay of a-mixture of compounds, LIP
expression is tested against progressively smaller subsets of the
compound pool (e.g., produced by standard purification techniques
such as HPLC or FPLC) until a single compound or minimal number of
effective compounds is demonstrated to modulate IAP expression.
[0168] Compounds may also be screened for their ability to enhance
IAP-mediated apoptosis. In this approach, the degree of apoptosis
in the presence of a candidate compound is compared to the degree
of apoptosis in its absence, under equivalent conditions. Again,
the screen may begin with a pool of candidate compounds, from which
one or more useful modulator compounds are isolated in a step-wise
fashion. Apoptosis activity may be measured by any standard assay,
for example, those described herein.
[0169] Another method for detecting compounds that modulate the
activity of IAPs is to screen for compounds that interact
physically with a given IAP polypeptide. These compounds may be
detected by adapting interaction trap expression systems known in
the art. These systems detect protein interactions using a
transcriptional activation assay and are generally described by
Gyuris et al. (Cell 75:791-803, 1993) and Field et al. (Nature
340:245-246, 1989), and are commercially available from Clontech
(Palo Alto, Calif.). In addition, PCT Publication WO 95/28497
describes an interaction trap assay in which proteins involved in
apoptosis, by virtue of their interaction with Bcl-2, are detected.
A similar method may be used to identify proteins and other
compounds that interact with IAPs.
[0170] Compounds or molecules that function as modulators of
IAP-mediated cell death may include peptide and non-peptide
molecules such as those present in cell extracts, mammalian serum,
or growth medium in which mammalian cells have been-cultured.
TABLE-US-00002 TABLE 2 OLIGONUCLEOTIDE PRIMERS FOR THE SPECIFIC
RT-PCR AMPLIFICATION OF IAP GENES Size of IAP Forward Printer
Reverse Primer Product Gene (nucleotide position*) (nucleotide
position*) (bp) h-xiap p2415 (876-896) p2449 (1291-1311) 435 m-xiap
p2566 (458-478) p2490 (994-1013) 555 h-hiap1 p2465 (827-847) p2464
(1008-1038) 211 m-hiap1 p2687 (747-767) p2684 (1177-1197) 450 hiap2
p2595 (1562-1585) p2578 (2339-2363) 801.sup.a 618.sup.b m-hiap2
p2693 (1751-1772) p2734 (2078-2100) 349 *Nucleotide position as
determined from FIGS. 1-4 for each IAP gene .sup.aPCR product size
of hiap2a .sup.bPCR product size of hiap2b
EXAMPLE 15
Assignment of xiap, hiap-1 and hiap-2 to Chromosomes Xq25 and
11q22-23 by Fluorescence in Situ Hybridization (FISH)
[0171] Fluorescence in situ hybridization (FISH) was used to
identify the chromosomal location of xiap, hiap-1 and hiap-2.
[0172] A total of 101 metaphase spreads were examined with the xiap
probe, as described above. Symmetrical fluorescent signals on
either one or both homologs of chromosome Xq25 were observed in 74%
of the cells analyzed. Following staining with hiap-1 and hiap-2
probes, 56 cells were analyzed and doublet signals in the region
11q22-23 were observed in 83% of cells examined. The xiap gene was
mapped to Xq25 while the hiap-1 and hiap-2 genes were mapped at the
border of 11q22 and 11 q23 bands.
[0173] These experiments confirmed the location of the xiap gene on
chromosome Xq25. No highly consistent chromosomal abnormalities
involving band Xq25 have been reported so far in any malignancies.
However, deletions within this region are associated with a number
of immune system defects including X-linked lymphoproliferative
disease (Wu et al., Genomics 17:163-170, 1993).
[0174] Cytogenetic abnormalities of band 11q23 have been identified
in more than 50% of infant leukemias regardless of the phenotype
(Martinez-Climet et-al., Leukaemia-9:12994304-1995). Rearrangements
of the MLL Gene (mixed lineage leukemia or myeloid lymphoid
leukemia; Ziemin Van der Poel et al., Proc. Natl. Acad. Sci. USA
88:10735-10739, 1991) have been detected in 80% of cases with 11q23
translocation, however patients whose rearrangements clearly
involved regions other than the MLL gene were also reported
(Kobayashi et al., Blood 82:547-551, 1993). Thus, the IAP genes may
follow the Bcl-2 paradigm, and would therefore play an important
role in cancer transformation.
Incorporation by Reference
[0175] The following documents and all the references referred to
herein are incorporated by reference: U.S. Ser. No. 08/511,485,
filed Aug. 4, 1995; U.S. Ser. No. 08/576,956, filed Dec. 22, 1995;
PCT/IB96/01022, filed Aug. 5, 1996; U.S. Ser. No. 60/017,354, filed
Apr. 26, 1996; U.S. Ser. No. 60/030,931, filed Nov. 15, 1996
(Express Mail Labeling Number RB794124826US); U.S. Ser. No.
60/030,590, filed Nov. 14, 1996 (Express Mail Labeling Number
RB794124804US); U.S. Pat. No. 5,576,208, issued Nov. 19, 1996; and
PCT Application IB97/00142, filed Jan. 17, 1997 claiming priority
from UK 9601108.5, filed Jan. 19, 1996.
Other Embodiments
[0176] In other embodiments, the invention includes use of any
protein which is substantially identical to a mammalian IAP
polypeptides (FIGS. 1-6; SEQ ID NOs: 1-14); such homologs include
other substantially pure naturally-occurring mammalian IAP proteins
as well as allelic variants; natural mutants; induced mutants; DNA
sequences which encode proteins and also hybridize to the IAP DNA
sequences of FIGS. 1-6 (SEQ ID NOS: 1-14) under high stringency
conditions or, less preferably, under low stringency conditions
(e.g., washing at 2.times.SSC at 40.degree. C. with a probe length
of at least 40 nucleotides); and proteins specifically bound by
antisera directed to a IAP polypeptide. The term also includes
chimeric polypeptides that include a IAP portion.
[0177] The invention further includes use of analogs of any
naturally-occurring IAP polypeptide. Analogs can differ from the
naturally-occurring IAP protein by amino acid sequence differences,
by post-translational modifications, or by both. Analogs of the
invention will generally exhibit at least 85%, more preferably 90%,
and most preferably 95% or even 99% identity with all or part of a
naturally occurring IAP amino acid sequence. The length of sequence
comparison is at least 15 amino acid residues, preferably at least
25 amino acid residues, and more preferably more than 35 amino acid
residues. Modifications include in vivo and in vitro chemical
derivatization of polypeptides, e.g., acetylation, carboxylation,
phosphorylation, or glycosylation; such modifications may occur
during polypeptide synthesis or processing or following treatment
with isolated modifying enzymes. Analogs can also differ from the
naturally-occurring IAP polypeptide by alterations in primary
sequence. These include genetic variants, both natural and induced
(for example, resulting from random mutagenesis by irradiation or
exposure to ethanemethylsulfate or by site-specific mutagenesis as
described in Sambrook, Fritsch and Maniatis, Molecular Cloning: A
Laboratory Manual (2d ed.), CSH Press, 1989, or Ausubel et al.,
supra). Also included are cyclized peptides, molecules, and analogs
which contain residues other than L-amino acids, e.g., D-amino
acids or nonnaturally occurring or synthetic amino acids, e.g., B
or y amino acids. In addition to full-length polypeptides, the
invention also includes IAP polypeptide fragments. As used herein,
the term "fragment," means at least 20 contiguous amino acids,
preferably at least 30 contiguous amino acids, more preferably at
least 50 contiguous amino acids, and most preferably at least 60 to
80 or more contiguous amino acids. Fragments of IAP polypeptides
can be generated by methods known to those skilled in the art or
may result from normal protein processing (e.g., removal of amino
acids from the nascent polypeptide that are not required for
biological activity or removal of amino acids by alternative mRNA
splicing or alternative protein processing events).
[0178] Preferable fragments or analogs used according to the
methods of the invention are those which facilitate specific
detection of a IAP nucleic acid or amino acid sequence in a sample
to be diagnosed. Particularly useful IAP fragments for this purpose
include, without limitation, the amino acid fragments shown in
Table 2.
[0179] The methods of the invention may use antibodies prepared by
a variety of methods. For example, the IAP or NAIP polypeptide, or
antigenic fragments thereof, can be administered to an animal in
order to induce the production of polyclonal antibodies.
Alternatively, antibodies used as described herein may be
monoclonal antibodies, which are prepared using hybridoma
technology (see, e.g., Kohler et al., Nature 256:495, 1975; Kohler
et al., Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J.
Immunol. 6:292, 1976; Hammerling et al., In Monoclonal Antibodies
and T Cell Hybridomas, Elsevier, N.Y., 1981). The invention
features use of antibodies that specifically bind human or murine
IAP or NAIP polypeptides, or fragments thereof. In particular the
invention features "neutralizing" antibodies. By "neutralizing"
antibodies is meant antibodies that interfere with any of the
biological activities of IAP or NAIP polypeptides, particularly the
ability of IAPs to inhibit apoptosis. The neutralizing antibody may
reduce the ability of IAP polypeptides to inhibit polypeptides by,
preferably 50%, more preferably by 70%, and most preferably by 90%
or more. Any standard assay of apoptosis, including those described
herein, by those incorporated by reference and those in the art,
may be used to assess neutralizing antibodies.
[0180] In addition to intact monoclonal and polyclonal anti-IAP
antibodies, the invention features use of various genetically
engineered antibodies, humanized antibodies, and antibody
fragments, including F(ab')2, Fab', Fab, Fv and sFv fragments.
Antibodies can be humanized by methods known in the art, e.g.,
monoclonal antibodies with a desired binding specificity can be
commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo
Alto, Calif.). Fully human antibodies, such as those expressed in
transgenic animals, are also features of the invention (Green et
al., Nature Genetics 7:13-21, 1994).
[0181] Ladner (U.S. Pat. Nos. 4,946,778 and 4,704,692) describes
methods for preparing single polypeptide chain antibodies. Ward et
al. (Nature 341:544-546, 1989) describe the preparation of heavy
chain variable domains, which they term "single domain antibodies,"
which have high antigen-binding affinities. McCafferty et al.
(Nature 348:552-554, 1990) show that complete antibody V domains
can be displayed on the surface of fd bacteriophage, that the phage
bind specifically to antigen, and that rare phage (one in a
million) can be isolated after affinity chromatography. Boss et al.
(U.S. Pat. No. 4,816,397) describe--various-methods for producing
immunoglobulins, and immunologically functional fragments thereof,
which include at least the variable domains of the heavy and light
chain in a single host cell. Cabilly et al. (U.S. Pat. No.
4,816,567) describe methods for preparing chimeric antibodies.
Sequence CWU 1
1
17146PRTArtificial SequenceVARIANT(1)...(46)Xaa at 2, 3, 4, 5, 6,
7, 9, 10, 11, 17, 18, 19, 20, 21, 23, 25, 30, 31, 32, 34, 35, 38,
39, 40, 41, 42, and 45 can be any amino acid; Xaa at 8 can be Glu
or Asp; Xaa at 14 and 22 can be Val or Ile. 1Glu Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Cys Lys Xaa Cys Met 1 5 10 15Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Phe Xaa Pro Cys Gly His Xaa Xaa Xaa 20 25 30Cys Xaa
Xaa Cys Ala Xaa Xaa Xaa Xaa Xaa Cys Pro Xaa Cys 35 40
45268PRTArtificial SequenceVARIANT(1)...(68)Xaa at 1, 2, 3, 6, 9,
10, 14, 15, 18, 19, 20, 21, 24, 30, 32, 33, 35, 37, 40, 42, 43, 44,
45, 46, 47, 49, 50, 51, 53, 54, 55, 56, 57, 59, 60, 61, 62, 64 and
66 can be any amino acid; Xaa at 13, 16 and 17 can be any amino
acid or absent. 2Xaa Xaa Xaa Arg Leu Xaa Thr Phe Xaa Xaa Trp Pro
Xaa Xaa Xaa Xaa 1 5 10 15Xaa Xaa Xaa Xaa Xaa Leu Ala Xaa Ala Gly
Phe Tyr Tyr Xaa Gly Xaa 20 25 30Xaa Asp Xaa Val Xaa Cys Phe Xaa Cys
Xaa Xaa Xaa Xaa Xaa Xaa Trp 35 40 45Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa
Xaa His Xaa Xaa Xaa Xaa Pro Xaa 50 55 60Cys Xaa Phe
Val6535232DNAHomo sapiensvariation4623n can be any nucleotide
3gaaaaggtgg acaagtccta ttttcaagag aagatgactt ttaacagttt tgaaggatct
60aaaacttgtg tacctgcaga catcaataag gaagaagaat ttgtagaaga gtttaataga
120ttaaaaactt ttgctaattt tccaagtggt agtcctgttt cagcatcaac
actggcacga 180gcagggtttc tttatactgg tgaaggagat accgtgcggt
gctttagttg tcatgcagct 240gtagatagat ggcaatatgg agactcagca
gttggaagac acaggaaagt atccccaaat 300tgcagattta tcaacggctt
ttatcttgaa aatagtgcca cgcagtctac aaattctggt 360atccagaatg
gtcagtacaa agttgaaaac tatctgggaa gcagagatca ttttgcctta
420gacaggccat ctgagacaca tgcagactat cttttgagaa ctgggcaggt
tgtagatata 480tcagacacca tatacccgag gaaccctgcc atgtatagtg
aagaagctag attaaagtcc 540tttcagaact ggccagacta tgctcaccta
accccaagag agttagcaag tgctggactc 600tactacacag gtattggtga
ccaagtgcag tgcttttgtt gtggtggaaa actgaaaaat 660tgggaacctt
gtgatcgtgc ctggtcagaa cacaggcgac actttcctaa ttgcttcttt
720gttttgggcc ggaatcttaa tattcgaagt gaatctgatg ctgtgagttc
tgataggaat 780ttcccaaatt caacaaatct tccaagaaat ccatccatgg
cagattatga agcacggatc 840tttacttttg ggacatggat atactcagtt
aacaaggagc agcttgcaag agctggattt 900tatgctttag gtgaaggtga
taaagtaaag tgctttcact gtggaggagg gctaactgat 960tggaagccca
gtgaagaccc ttgggaacaa catgctaaat ggtatccagg gtgcaaatat
1020ctgttagaac agaagggaca agaatatata aacaatattc atttaactca
ttcacttgag 1080gagtgtctgg taagaactac tgagaaaaca ccatcactaa
ctagaagaat tgatgatacc 1140atcttccaaa atcctatggt acaagaagct
atacgaatgg ggttcagttt caaggacatt 1200aagaaaataa tggaggaaaa
aattcagata tctgggagca actataaatc acttgaggtt 1260ctggttgcag
atctagtgaa tgctcagaaa gacagtatgc aagatgagtc aagtcagact
1320tcattacaga aagagattag tactgaagag cagctaaggc gcctgcaaga
ggagaagctt 1380tgcaaaatct gtatggatag aaatattgct atcgtttttg
ttccttgtgg acatctagtc 1440acttgtaaac aatgtgctga agcagttgac
aagtgtccca tgtgctacac agtcattact 1500ttcaagcaaa aaatttttat
gtcttaatct aactctatag taggcatgtt atgttgttct 1560tattaccctg
attgaatgtg tgatgtgaac tgactttaag taatcaggat tgaattccat
1620tagcatttgc taccaagtag gaaaaaaaat gtacatggca gtgttttagt
tggcaatata 1680atctttgaat ttcttgattt ttcagggtat tagctgtatt
atccattttt tttactgtta 1740tttaattgaa accatagact aagaataaga
agcatcatac tataactgaa cacaatgtgt 1800attcatagta tactgattta
atttctaagt gtaagtgaat taatcatctg gattttttat 1860tcttttcaga
taggcttaac aaatggagct ttctgtatat aaatgtggag attagagtta
1920atctccccaa tcacataatt tgttttgtgt gaaaaaggaa taaattgttc
catgctggtg 1980gaaagataga gattgttttt agaggttggt tgttgtgttt
taggattctg tccattttct 2040tttaaagtta taaacacgta cttgtgcgaa
ttattttttt aaagtgattt gccatttttg 2100aaagcgtatt taatgataga
atactatcga gccaacatgt actgacatgg aaagatgtca 2160aagatatgtt
aagtgtaaaa tgcaagtggc aaaacactat gtatagtctg agccagatca
2220aagtatgtat gtttttaata tgcatagaac aaaagatttg gaaagatata
caccaaactg 2280ttaaatgtgg tttctcttcg gggagggggg gattggggga
ggggccccag aggggtttta 2340taggggcctt ttcactttct acttttttca
ttttgttctg ttcgaatttt ttataagtat 2400gtattacttt tgtaatcaga
atttttagaa agtattttgc tgatttaaag gcttaggcat 2460gttcaaacgc
ctgcaaaact acttatcact cagctttagt ttttctaatc caagaaggca
2520gggcagttaa cctttttggt gccaatgtga aatgtaaatg attttatgtt
tttcctgctt 2580tgtggatgaa aaatatttct gagtggtagt tttttgacag
gtagaccatg tcttatcttg 2640tttcaaaata agtatttctg attttgtaaa
atgaaatata aaatatgtct cagatcttcc 2700aattaattag taaggattca
tccttaatcc ttgctagttt aagcctgcct aagtcacttt 2760actaaaagat
ctttgttaac tcagtatttt aaacatctgt cagcttatgt aggtaaaagt
2820agaagcatgt ttgtacactg cttgtagtta tagtgacagc tttccatgtt
gagattctca 2880tatcatcttg tatcttaaag tttcatgtga gtttttaccg
ttaggatgat taagatgtat 2940ataggacaaa atgttaagtc tttcctctac
ctacatttgt tttcttggct agtaatagta 3000gtagatactt ctgaaataaa
tgttctctca agatccttaa aacctcttgg aaattataaa 3060aatattggca
agaaaagaag aatagttgtt taaatatttt ttaaaaaaca cttgaataag
3120aatcagtagg gtataaacta gaagtttaaa aatgcctcat agaacgtcca
gggtttacat 3180tacaagattc tcacaacaaa cccattgtag aggtgagtaa
ggcatgttac tacagaggaa 3240agtttgagag taaaactgta aaaaattata
tttttgttgt actttctaag agaaagagta 3300ttgttatgtt ctcctaactt
ctgttgatta ctactttaag tgatattcat ttaaaacatt 3360gcaaatttat
tttatttatt taattttctt tttgagatgg agtcttgctt gtcacccagg
3420ctggagtgca gtggagtgat ctctgctcac tgcaacctcc gccttctggg
ttcaagcgat 3480tctcgtgcct cagcttcctg agtagctgga attacaggca
ggtgccacca tgcccgacta 3540attttttttt atttttagta gagacggggt
ttcaccatgt tggccaggct ggtatcaaac 3600tcctgacctc aagagatcca
ctcgccttgc cctcccaaag tgctgggatt acaggcttga 3660gccaccacgc
ccggctaaaa cattgcaaat ttaaatgaga gttttaaaaa ttaaataatg
3720actgccctgt ttctgtttta gtatgtaaat cctcagttct tcacctttgc
actgtctgcc 3780acttagtttg gttatatagt cattaacttg aatttggtct
gtatagtcta gactttaaat 3840ttaaagtttt ctacaagggg agaaaagtgt
taaaattttt aaaatatgtt ttccaggaca 3900cttcacttcc aagtcaggta
ggtagttcaa tctagttgtt agccaaggac tcaaggactg 3960aattgtttta
acataaggct tttcctgttc tgggagccgc acttcattaa aattcttcta
4020aaacttgtat gtttagagtt aagcaagact ttttttcttc ctctccatga
gttgtgaaat 4080ttaatgcaca acgctgatgt ggctaacaag tttattttaa
gaattgttta gaaatgctgt 4140tgcttcaggt tcttaaaatc actcagcact
ccaacttcta atcaaatttt tggagactta 4200acagcatttg tctgtgtttg
aactataaaa agcaccggat cttttccatc taattccgca 4260aaaattgatc
atttgcaaag tcaaaactat agccatatcc aaatcttttc cccctcccaa
4320gagttctcag tgtctacatg tagactattc cttttctgta taaagttcac
tctaggattt 4380caagtcacca cttattttac attttagtca tgcaaagatt
caagtagttt tgcaataagt 4440acttatcttt atttgtaata atttagtctg
ctgatcaaaa gcattgtctt aatttttgag 4500aactggtttt agcatttaca
aactaaattc cagttaatta attaatagct ttatattgcc 4560tttcctgcta
catttggttt tttcccctgt ccctttgatt acgggctaag gtagggtaag
4620anngggtgta gtgagtgtat ataatgtgat ttggccctgt gtattatgat
attttgttat 4680ttttgttgtt atattattta catttcagta gttgtttttt
gtgtttccat tttaggggat 4740aaaatttgta ttttgaacta tgaatggaga
ctaccgcccc agcattagtt tcacatgata 4800taccctttaa acccgaatca
ttgttttatt tcctgattac acaggtgttg aatggggaaa 4860ggggctagta
tatcagtagg atatactatg ggatgtatat atatcattgc tgttagagaa
4920atgaaataaa atggggctgg gctcagtggc tcacgcctgt aatcccagca
ctttgggagg 4980ctgaggcagg tggatcacga ggtcaggaga tcgagaccat
cctggctaac acggtgaaac 5040cccgtctcta ctaaaaaaca gaaaattagc
cgggcgtggt ggcgggcgcc tgtagtccca 5100gctactcggg aggctgaggc
aggagaatgg tgtgaacccg ggaggcagag cttgcagtga 5160gccgagatct
cgccactgca ctccagcctg ggcaacagag caagactctg tctcaaaaaa
5220aaaaaaaaaa ag 52324497PRTHomo sapiens 4Met Thr Phe Asn Ser Phe
Glu Gly Ser Lys Thr Cys Val Pro Ala Asp 1 5 10 15Ile Asn Lys Glu
Glu Glu Phe Val Glu Glu Phe Asn Arg Leu Lys Thr 20 25 30Phe Ala Asn
Phe Pro Ser Gly Ser Pro Val Ser Ala Ser Thr Leu Ala 35 40 45Arg Ala
Gly Phe Leu Tyr Thr Gly Glu Gly Asp Thr Val Arg Cys Phe 50 55 60Ser
Cys His Ala Ala Val Asp Arg Trp Gln Tyr Gly Asp Ser Ala Val65 70 75
80Gly Arg His Arg Lys Val Ser Pro Asn Cys Arg Phe Ile Asn Gly Phe
85 90 95Tyr Leu Glu Asn Ser Ala Thr Gln Ser Thr Asn Ser Gly Ile Gln
Asn 100 105 110Gly Gln Tyr Lys Val Glu Asn Tyr Leu Gly Ser Arg Asp
His Phe Ala 115 120 125Leu Asp Arg Pro Ser Glu Thr His Ala Asp Tyr
Leu Leu Arg Thr Gly 130 135 140Gln Val Val Asp Ile Ser Asp Thr Ile
Tyr Pro Arg Asn Pro Ala Met145 150 155 160Tyr Cys Glu Glu Ala Arg
Leu Lys Ser Phe Gln Asn Trp Pro Asp Tyr 165 170 175Ala His Leu Thr
Pro Arg Glu Leu Ala Ser Ala Gly Leu Tyr Tyr Thr 180 185 190Gly Ile
Gly Asp Gln Val Gln Cys Phe Cys Cys Gly Gly Lys Leu Lys 195 200
205Asn Trp Glu Pro Cys Asp Arg Ala Trp Ser Glu His Arg Arg His Phe
210 215 220Pro Asn Cys Phe Phe Val Leu Gly Arg Asn Leu Asn Ile Arg
Ser Glu225 230 235 240Ser Asp Ala Val Ser Ser Asp Arg Asn Phe Pro
Asn Ser Thr Asn Leu 245 250 255Pro Arg Asn Pro Ser Met Ala Asp Tyr
Glu Ala Arg Ile Phe Thr Phe 260 265 270Gly Thr Trp Ile Tyr Ser Val
Asn Lys Glu Gln Leu Ala Arg Ala Gly 275 280 285Phe Tyr Ala Leu Gly
Glu Gly Asp Lys Val Lys Cys Phe His Cys Gly 290 295 300Gly Gly Leu
Thr Asp Trp Lys Pro Ser Glu Asp Pro Trp Glu Gln His305 310 315
320Ala Lys Trp Tyr Pro Gly Cys Lys Tyr Leu Leu Glu Gln Lys Gly Gln
325 330 335Glu Tyr Ile Asn Asn Ile His Leu Thr His Ser Leu Glu Glu
Cys Leu 340 345 350Val Arg Thr Thr Glu Lys Thr Pro Ser Leu Thr Arg
Arg Ile Asp Asp 355 360 365Thr Ile Phe Gln Asn Pro Met Val Gln Glu
Ala Ile Arg Met Gly Phe 370 375 380Ser Phe Lys Asp Ile Lys Lys Ile
Met Glu Glu Lys Ile Gln Ile Ser385 390 395 400Gly Ser Asn Tyr Lys
Ser Leu Glu Val Leu Val Ala Asp Leu Val Asn 405 410 415Ala Gln Lys
Asp Ser Met Gln Asp Glu Ser Ser Gln Thr Ser Leu Gln 420 425 430Lys
Glu Ile Ser Thr Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Lys 435 440
445Leu Cys Lys Ile Cys Met Asp Arg Asn Ile Ala Ile Val Phe Val Pro
450 455 460Cys Gly His Leu Val Thr Cys Lys Gln Cys Ala Glu Ala Val
Asp Lys465 470 475 480Cys Pro Met Cys Tyr Thr Val Ile Thr Phe Lys
Gln Lys Ile Phe Met 485 490 495Ser56669DNAHomo
sapiensvariation(3677)...(3951)n can be any nucleotide 5ttgctctgtc
acccagtttg gagtgcagtt atgcagtctc acactgcaag ctctgcctca 60tgggctcaag
tgaacctcct gcctcagcct ctcaagtagc tgggaccaca ggcaggtgcc
120accatgtctg gctaattttt gagtttcttt gtagagatgg tgttttgcca
agtcacccag 180tttgaggctg gtctcaaaca cctgggctca agcaatccat
ctacctcagc ctcccaaagt 240gctgggatta caggagtgag ccatggcatg
aggccttgtg gggtgtctct tttaaatgaa 300agcatactct gtttacgtat
ttgatatgaa ggaatatcct tcctttccac aaagacaaaa 360attatcctat
ttttctcaaa acatatgtcc tttttctcta cttttcattt ttgttacttt
420tgatggacac atgtgttaca ttgatttcac tttctcataa ttctgctgta
agaaaaacaa 480tagtgccagt tcaatgacaa atagcaacag tctgttattg
ctagactgtt actgttagtg 540gagactacca gaacagtcag tcccagtgtc
agggaatcaa agagaacatg ttccctctct 600aaagggcaca gctgctgctc
agctttagct gattgctgcc ctgcaggact ataggcccag 660tgttgctaga
tcttttgatg tttcaagaga agcttggaat ctagaatgtg atgggaagtc
720tcttacattt aaacatgttg gcaattaatg gtaagattta aaaatactgt
ggtccaagaa 780aaaaatggat ttggaaactg gattaaattc aaatgaggca
tgcagattaa tctacagcat 840ggtacaatgt gaattttctg gtttctttaa
ttgcactgta attaggtaag atgttagctt 900tggggaagct aagtgcagag
tatgcagaaa ctattatttt tgtaagtttt ctctaagtat 960aaataaattt
caaaataaaa ataaaaactt agtaaagaac tataatgcaa ttctatgtaa
1020gccaaacata atatgtcttc cagtttgaaa cctctgggtt ttattttatt
ttattttatt 1080tttgagacag agtcttgctg tgtcacccag gctggagtgt
agtggcacta tttcggccca 1140ctgcaacctc cacctcccag gctcaaatga
ttctcctgcc tcagcctccg gagtagctgg 1200gattacaggc gcgtaccacc
acacccagct aatttttgta tttttagtag agatggggtt 1260tcaccatttt
ggccaggctg gttttgaact cctgacctca agtgatccac ttgtcttggc
1320ctcccaaaat gctgggatta caggcgtgag ccactgcacc aggcagaggc
ctctgttttt 1380tatctctttt tggcctctac agtgcctagt aaagcacctg
atacatggta aacgatcagt 1440aattactagt actctatttt ggagaaaatg
attttttaaa aagtcattgt gttccatcca 1500tgagtcgttt gagttttaaa
actgtctttt tgtttgtttt tgaacaggtt tacaaaggag 1560gaaaacgact
tcttctagat ttttttttca gtttcttcta taaatcaaaa catctcaaaa
1620tggagaccta aaatccttaa agggacttag tctaatctcg ggaggtagtt
ttgtgcatgg 1680gtaaacaaat taagtattaa ctggtgtttt actatccaaa
gaatgctaat tttataaaca 1740tgatcgagtt atataaggta taccataatg
agtttgattt tgaatttgat ttgtggaaat 1800aaaggaaaag tgattctagc
tggggcatat tgttaaagca tttttttcag agttggccag 1860gcagtctcct
actggcacat tctcccatta tgtagaatag aaatagtacc tgtgtttggg
1920aaagatttta aaatgagtga cagttatttg gaacaaagag ctaataatca
atccactgca 1980aattaaagaa acatgcagat gaaagttttg acacattaaa
atacttctac agtgacaaag 2040aaaaatcaag aacaaagctt tttgatatgt
gcaacaaatt tagaggaagt aaaaagataa 2100atgtgatgat tggtcaagaa
attatccagt tatttacaag gccactgata ttttaaacgt 2160ccaaaagttt
gtttaaatgg gctgttaccg ctgagaatga tgaggatgag aatgatggtt
2220gaaggttaca ttttaggaaa tgaagaaact tagaaaatta atataaagac
agtgatgaat 2280acaaagaaga tttttataac aatgtgtaaa atttttggcc
agggaaagga atattgaagt 2340tagatacaat tacttacctt tgagggaaat
aattgttggt aatgagatgt gatgtttctc 2400ctgccacctg gaaacaaagc
attgaagtct gcagttgaaa agcccaacgt ctgtgagatc 2460caggaaacca
tgcttgcaaa ccactggtaa aaaaaaaaaa aaaaaaaaaa aaagccacag
2520tgacttgctt attggtcatt gctagtatta tcgactcaga acctctttac
taatggctag 2580taaatcataa ttgagaaatt ctgaattttg acaaggtctc
tgctgttgaa atggtaaatt 2640tattattttt tttgtcatga taaattctgg
ttcaaggtat gctatccatg aaataatttc 2700tgaccaaaac taaattgatg
caatttgatt atccatctta gcctacagat ggcatctggt 2760aacttttgac
tgttttaaaa aataaatcca ctatcagagt agatttgatg ttggcttcag
2820aaacatttag aaaaacaaaa gttcaaaaat gttttcagga ggtgataagt
tgaataactc 2880tacaatgtta gttctttgag ggggacaaaa aatttaaaat
ctttgaaagg tcttatttta 2940cagccatatc taaattatct taagaaaatt
tttaacaaag ggaatgaaat atatatcatg 3000attctgtttt tccaaaagta
acctgaatat agcaatgaag ttcagttttg ttattggtag 3060tttgggcaga
gtctcttttt gcagcacctg ttgtctacca taattacaga ggacatttcc
3120atgttctagc caagtatact attagaataa aaaaacttaa cattgagttg
cttcaacagc 3180atgaaactga gtccaaaaga ccaaatgaac aaacacatta
atctctgatt atttatttta 3240aatagaatat ttaattgtgt aagatctaat
agtatcatta tacttaagca atcatattcc 3300tgatgatcta tgggaaataa
ctattattta attaatattg aaaccaggtt ttaagatgtg 3360ttagccagtc
ctgttactag taaatctctt tatttggaga gaaattttag attgttttgt
3420tctccttatt agaaggattg tagaaagaaa aaaatgacta attggagaaa
aattggggat 3480atatcatatt tcactgaatt caaaatgtct tcagttgtaa
atcttaccat tattttacgt 3540acctctaaga aataaaagtg cttctaatta
aaatatgatg tcattaatta tgaaatactt 3600cttgataaca gaagttttaa
aatagccatc ttagaatcag tgaaatatgg taatgtatta 3660ttttcctcct
ttgagtnagg tcttgtgctt tttnttcctg gccactaaat ntcaccatnt
3720ccaanaagca aantaaacct attctgaata tttttgctgt gaaacacttg
ncagcagagc 3780tttcccncca tgnnagaagc ttcatgagtc acacattaca
tctttgggtt gattgaatgc 3840cactgaaaca tttctagtag cctggagnag
ttgacctacc tgtggagatg cctgccatta 3900aatggcatcc tgatggctta
atacacatca ctcttctgtg nagggtttta attttcaaca 3960cagcttactc
tgtagcatca tgtttacatt gtatgtataa agattatacn aaggtgcaat
4020tgtgtatttc ttccttaaaa tgtatcagta taggatttag aatctccatg
ttgaaactct 4080aaatgcatag aaataaaaat aataaaaaat ttttcatttt
ggcttttcag cctagtatta 4140aaactgataa aagcaaagcc atgcacaaaa
ctacctccct agagaaaggc tagtcccttt 4200tcttccccat tcatttcatt
atgaacatag tagaaaacag catattctta tcaaatttga 4260tgaaaagcgc
caacacgttt gaactgaaat acgacttgtc atgtgaactg taccgaatgt
4320ctacgtattc cacttttcct gctggggttc ctgtctcaga aaggagtctt
gctcgtgctg 4380gtttctatta cactggtgtg aatgacaagg tcaaatgctt
ctgttgtggc ctgatgctgg 4440ataactggaa aagaggagac agtcctactg
aaaagcataa aaagttgtat cctagctgca 4500gattcgttca gagtctaaat
tccgttaaca acttggaagc tacctctcag cctacttttc 4560cttcttcagt
aacacattcc acacactcat tacttccggg tacagaaaac agtggatatt
4620tccgtggctc ttattcaaac tctccatcaa atcctgtaaa ctccagagca
aatcaagaat 4680tttctgcctt gatgagaagt tcctacccct gtccaatgaa
taacgaaaat gccagattac 4740ttacttttca gacatggcca ttgacttttc
tgtcgccaac agatctggca cgagcaggct 4800tttactacat aggacctgga
gacagagtgg cttgctttgc ctgtggtgga aaattgagca 4860attgggaacc
gaaggataat gctatgtcag aacacctgag acattttccc aaatgcccat
4920ttatagaaaa tcagcttcaa gacacttcaa gatacacagt ttctaatctg
agcatgcaga 4980cacatgcagc ccgctttaaa acattcttta actggccctc
tagtgttcta gttaatcctg 5040agcagcttgc aagtgcgggt ttttattatg
tgggtaacag tgatgatgtc aaatgctttt 5100gctgtgatgg tggactcagg
tgttgggaat ctggagatga tccatgggtt caacatgcca 5160agtggtttcc
aaggtgtgag tacttgataa gaattaaagg acaggagttc atccgtcaag
5220ttcaagccag ttaccctcat ctacttgaac agctgctatc cacatcagac
agcccaggag 5280atgaaaatgc agagtcatca attatccatt ttgaacctgg
agaagaccat tcagaagatg 5340caatcatgat gaatactcct gtgattaatg
ctgccgtgga aatgggcttt agtagaagcc 5400tggtaaaaca gacagttcag
agaaaaatcc tagcaactgg agagaattat agactagtca 5460atgatcttgt
gttagactta ctcaatgcag aagatgaaat aagggaagag gagagagaaa
5520gagcaactga ggaaaaagaa tcaaatgatt tattattaat ccggaagaat
agaatggcac 5580tttttcaaca tttgacttgt gtaattccaa tcctggatag
tctactaact gccggaatta 5640ttaatgaaca agaacatgat gttattaaac
agaagacaca gacgtcttta caagcaagag 5700aactgattga tacgatttta
gtaaaaggaa atattgcagc cactgtattc agaaactctc 5760tgcaagaagc
tgaagctgtg ttatatgagc atttatttgt gcaacaggac ataaaatata
5820ttcccacaga agatgtttca gatctaccag tggaagaaca attgcggaga
ctacaagaag 5880aaagaacatg taaagtgtgt atggacaaag aagtgtccat
agtgtttatt ccttgtggtc 5940atctagtagt atgcaaagat tgtgctcctt
ctttaagaaa gtgtcctatt tgtaggagta 6000caatcaaggg tacagttcgt
acatttcttt catgaagaag aaccaaaaca tcgtctaaac 6060tttagaatta
atttattaaa tgtattataa ctttaacttt tatcctaatt tggtttcctt
6120aaaattttta tttatttaca actcaaaaaa cattgttttg tgtaacatat
ttatatatgt 6180atctaaacca tatgaacata tattttttag aaactaagag
aatgataggc ttttgttctt 6240atgaacgaaa aagaggtagc actacaaaca
caatattcaa tcaaaatttc agcattattg 6300aaattgtaag tgaagtaaaa
cttaagatat ttgagttaac ctttaagaat tttaaatatt 6360ttggcattgt
actaataccg ggaacatgaa gccaggtgtg gtggtatgtg cctgtagtcc
6420caggctgagg caagagaatt acttgagccc aggagtttga atccatcctg
ggcagcatac 6480tgagaccctg cctttaaaaa caaacagaac aaaaacaaaa
caccagggac acatttctct 6540gtcttttttg atcagtgtcc tatacatcga
aggtgtgcat atatgttgaa tcacatttta 6600gggacatggt gtttttataa
agaattctgt gagaaaaaat ttaataaagc aaccaaaaaa 6660aaaaaaaaa
66696604PRTHomo sapiens 6Met Asn Ile Val Glu Asn Ser Ile Phe Leu
Ser Asn Leu Met Lys Ser 1 5 10 15Ala Asn Thr Phe Glu Leu Lys Tyr
Asp Leu Ser Cys Glu Leu Tyr Arg 20 25 30Met Ser Thr Tyr Ser Thr Phe
Pro Ala Gly Val Pro Val Ser Glu Arg 35 40 45Ser Leu Ala Arg Ala Gly
Phe Tyr Tyr Thr Gly Val Asn Asp Lys Val 50 55 60Lys Cys Phe Cys Cys
Gly Leu Met Leu Asp Asn Trp Lys Arg Gly Asp65 70 75 80Ser Pro Thr
Glu Lys His Lys Lys Leu Tyr Pro Ser Cys Arg Phe Val 85 90 95Gln Ser
Leu Asn Ser Val Asn Asn Leu Glu Ala Thr Ser Gln Pro Thr 100 105
110Phe Pro Ser Ser Val Thr His Ser Thr His Ser Leu Leu Pro Gly Thr
115 120 125Glu Asn Ser Gly Tyr Phe Arg Gly Ser Tyr Ser Asn Ser Pro
Ser Asn 130 135 140Pro Val Asn Ser Arg Ala Asn Gln Glu Phe Ser Ala
Leu Met Arg Ser145 150 155 160Ser Tyr Pro Cys Pro Met Asn Asn Glu
Asn Ala Arg Leu Leu Thr Phe 165 170 175Gln Thr Trp Pro Leu Thr Phe
Leu Ser Pro Thr Asp Leu Ala Arg Ala 180 185 190Gly Phe Tyr Tyr Ile
Gly Pro Gly Asp Arg Val Ala Cys Phe Ala Cys 195 200 205Gly Gly Lys
Leu Ser Asn Trp Glu Pro Lys Asp Asn Ala Met Ser Glu 210 215 220His
Leu Arg His Phe Pro Lys Cys Pro Phe Ile Glu Asn Gln Leu Gln225 230
235 240Asp Thr Ser Arg Tyr Thr Val Ser Asn Leu Ser Met Gln Thr His
Ala 245 250 255Ala Arg Phe Lys Thr Phe Phe Asn Trp Pro Ser Ser Val
Leu Val Asn 260 265 270Pro Glu Gln Leu Ala Ser Ala Gly Phe Tyr Tyr
Val Gly Asn Ser Asp 275 280 285Asp Val Lys Cys Phe Cys Cys Asp Gly
Gly Leu Arg Cys Trp Glu Ser 290 295 300Gly Asp Asp Pro Trp Val Gln
His Ala Lys Trp Phe Pro Arg Cys Glu305 310 315 320Tyr Leu Ile Arg
Ile Lys Gly Gln Glu Phe Ile Arg Gln Val Gln Ala 325 330 335Ser Tyr
Pro His Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp Ser Pro 340 345
350Gly Asp Glu Asn Ala Glu Ser Ser Ile Ile His Leu Glu Pro Gly Glu
355 360 365Asp His Ser Glu Asp Ala Ile Met Met Asn Thr Pro Val Ile
Asn Ala 370 375 380Ala Val Glu Met Gly Phe Ser Arg Ser Leu Val Lys
Gln Thr Val Gln385 390 395 400Arg Lys Ile Leu Ala Thr Gly Glu Asn
Tyr Arg Leu Val Asn Asp Leu 405 410 415Val Leu Asp Leu Leu Asn Ala
Glu Asp Glu Ile Arg Glu Glu Glu Arg 420 425 430Glu Arg Ala Thr Glu
Glu Lys Glu Ser Asn Asp Leu Leu Leu Ile Arg 435 440 445Lys Asn Arg
Met Ala Leu Phe Gln His Leu Thr Cys Val Ile Pro Ile 450 455 460Leu
Asp Ser Leu Leu Thr Ala Gly Ile Ile Asn Glu Gln Glu His Asp465 470
475 480Val Ile Lys Gln Lys Thr Gln Thr Ser Leu Gln Ala Arg Glu Leu
Ile 485 490 495Asp Thr Ile Leu Val Lys Gly Asn Ile Ala Ala Thr Val
Phe Arg Asn 500 505 510Ser Leu Gln Glu Ala Glu Ala Val Leu Tyr Glu
His Leu Phe Val Gln 515 520 525Gln Asp Ile Lys Tyr Ile Pro Thr Glu
Asp Val Ser Asp Leu Pro Val 530 535 540Glu Glu Gln Leu Arg Arg Leu
Pro Glu Glu Arg Thr Cys Lys Val Cys545 550 555 560Met Asp Lys Glu
Val Ser Ile Val Phe Ile Pro Cys Gly His Leu Val 565 570 575Val Cys
Lys Asp Cys Ala Pro Ser Leu Arg Lys Cys Pro Ile Cys Arg 580 585
590Ser Thr Ile Lys Gly Thr Val Arg Thr Phe Leu Ser 595
60073732DNAHomo sapiens 7gagcgcccgg gctgatccga gccgagcggg
ccgtatctcc ttgtcggcgc cgctgattcc 60cggctctgcg gaggcctcta ggcagccgcg
cagcttccgt gtttgctgcg cccgcactgc 120gatttacaac cctgaagaat
ctccctatcc ctattttgtc cccctgcagt aataaatccc 180attatggaga
tctcgaaact ttataaaggg atatagtttg aattctatgg agtgtaattt
240tgtgtatgaa ttatattttt aaaacattga agagttttca gaaagaaggc
tagtagagtt 300gattactgat actttatgct aagcagtact tttttggtag
tacaatattt tgttaggcgt 360ttctgataac actagaaagg acaagtttta
tcttgtgata aattgattaa tgtttacaac 420atgactgata attatagctg
aatagtcctt aaatgatgaa caggttattt agtttttaaa 480tgcagtgtaa
aaagtgtgct gtggaaattt tatggctaac taagtttatg gagaaaatac
540cttcagttga tcaagaataa tagtggtata caaagttagg aagaaagtca
acatgatgct 600gcaggaaatg gaaacaaata caaatgatat ttaacaaaga
tagagtttac agtttttgaa 660ctttaagcca aattcatttg acatcaagca
ctatagcagg cacaggttca acaaagcttg 720tgggtattga cttcccccaa
aagttgtcag ctgaagtaat ttagcccact taagtaaata 780ctatgatgat
aagctgtgtg aacttagctt ttaaatagtg tgaccatatg aaggttttaa
840ttacttttgt ttattggaat aaaatgagat tttttgggtt gtcatgttaa
agtgcttata 900gggaaagaag cctgcatata attttttacc ttgtggcata
atcagtaatt ggtctgttat 960tcaggcttca tagcttgtaa ccaaatataa
ataaaaggca taatttaggt attctatagt 1020tgcttagaat tttgttaata
taaatctctg tgaaaaatca aggagtttta atattttcag 1080aagtgcatcc
acctttcagg gctttaagtt agtattaact caagattatg aacaaatagc
1140acttaggtta cctgaaagag ttactacaac cccaaagagt tgtgttctaa
gtagtatctt 1200ggtaattcag agagatactc atcctacctg aatataaact
gagataaatc cagtaaagaa 1260agtgtagtaa attctacata agagtctatc
attgatttct ttttgtggta aaaatcttag 1320ttcatgtgaa gaaatttcat
gtgaatgttt tagctatcaa acagtactgt cacctactca 1380tgcacaaaac
tgcctcccaa agacttttcc caggtccctc gtatcaaaac attaagagta
1440taatggaaga tagcacgatc ttgtcagatt ggacaaacag caacaaacaa
aaaatgaagt 1500atgacttttc ctgtgaactc tacagaatgt ctacatattc
aactttcccc gccggggtgc 1560ctgtctcaga aaggagtctt gctcgtgctg
gtttttatta tactggtgtg aatgacaagg 1620tcaaatgctt ctgttgtggc
ctgatgctgg ataactggaa actaggagac agtcctattc 1680aaaagcataa
acagctatat cctagctgta gctttattca gaatctggtt tcagctagtc
1740tgggatccac ctctaagaat acgtctccaa tgagaaacag ttttgcacat
tcattatctc 1800ccaccttgga acatagtagc ttgttcagtg gttcttactc
cagcctttct ccaaaccctc 1860ttaattctag agcagttgaa gacatctctt
catcgaggac taacccctac agttatgcaa 1920tgagtactga agaagccaga
tttcttacct accatatgtg gccattaact tttttgtcac 1980catcagaatt
ggcaagagct ggtttttatt atataggacc tggagatagg gtagcctgct
2040ttgcctgtgg tgggaagctc agtaactggg aaccaaagga tgatgctatg
tcagaacacc 2100ggaggcattt tcccaactgt ccatttttgg aaaattctct
agaaactctg aggtttagca 2160tttcaaatct gagcatgcag acacatgcag
ctcgaatgag aacatttatg tactggccat 2220ctagtgttcc agttcagcct
gagcagcttg caagtgctgg tttttattat gtgggtcgca 2280atgatgatgt
caaatgcttt tgttgtgatg gtggcttgag gtgttgggaa tctggagatg
2340atccatgggt agaacatgcc aagtggtttc caaggtgtga gttcttgata
cgaatgaaag 2400gccaagagtt tgttgatgag attcaaggta gatatcctca
tcttcttgaa cagctgttgt 2460caacttcaga taccactgga gaagaaaatg
ctgacccacc aattattcat tttggacctg 2520gagaaagttc ttcagaagat
gctgtcatga tgaatacacc tgtggttaaa tctgccttgg 2580aaatgggctt
taatagagac ctggtgaaac aaacagttca aagtaaaatc ctgacaactg
2640gagagaacta taaaacagtt aatgatattg tgtcagcact tcttaatgct
gaagatgaaa 2700aaagagaaga ggagaaggaa aaacaagctg aagaaatggc
atcagatgat ttgtcattaa 2760ttcggaagaa cagaatggct ctctttcaac
aattgacatg tgtgcttcct atcctggata 2820atcttttaaa ggccaatgta
attaataaac aggaacatga tattattaaa caaaaaacac 2880agataccttt
acaagcgaga gaactgattg ataccatttt ggttaaagga aatgctgcgg
2940ccaacatctt caaaaactgt ctaaaagaaa ttgactctac attgtataag
aacttatttg 3000tggataagaa tatgaagtat atcccaacag aagatgtttc
aggtctgtca ctggaagaac 3060aattgaggag gttgcaagaa gaacgaactt
gtaaagtgtg tatggacaaa gaagtttctg 3120ttgtatttat tccttgtggt
catctggtag tatgccagga atgtgcccct tctctaagaa 3180aatgccctat
ttgcaggggt ataatcaagg gtactgttcg tacatttctc tcttaaagaa
3240aaatagtcta tattttaacc tgcataaaaa ggtctttaaa atattgttga
acacttgaag 3300ccatctaaag taaaaaggga attatgagtt tttcaattag
taacattcat gttctagtct 3360gctttggtac taataatctt gtttctgaaa
agatggtatc atatatttaa tcttaatctg 3420tttatttaca agggaagatt
tatgtttggt gaactatatt agtatgtatg tgtacctaag 3480ggagtagtgt
cactgcttgt tatgcatcat ttcaggagtt actggatttg ttgttctttc
3540agaaagcttt gaatactaaa ttatagtgta gaaaagaact ggaaaccagg
aactctggag 3600ttcatcagag ttatggtgcc gaattgtctt tggtgctttt
cacttgtgtt ttaaaataag 3660gatttttctc ttatttctcc ccctagtttg
tgagaaacat ctcaataaag tgctttaaaa 3720agaaaaaaaa aa 37328618PRTHomo
sapiens 8Met His Lys Thr Ala Ser Gln Arg Leu Phe Pro Gly Pro Ser
Tyr Gln 1 5 10 15Asn Ile Lys Ser Ile Met Glu Asp Ser Thr Ile Leu
Ser Asp Trp Thr 20 25 30Asn Ser Asn Lys Gln Lys Met Lys Tyr Asp Phe
Ser Cys Glu Leu Tyr 35 40 45Arg Met Ser Thr Tyr Ser Thr Phe Pro Ala
Gly Val Pro Val Ser Glu 50 55 60Arg Ser Leu Ala Arg Ala Gly Phe Tyr
Tyr Thr Gly Val Asn Asp Lys65 70 75 80Val Lys Cys Phe Cys Cys Gly
Leu Met Leu Asp Asn Trp Lys Leu Gly 85 90 95Asp Ser Pro Ile Gln Lys
His Lys Gln Leu Tyr Pro Ser Cys Ser Phe 100 105 110Ile Gln Asn Leu
Val Ser Ala Ser Leu Gly Ser Thr Ser Lys Asn Thr 115 120 125Ser Pro
Met Arg Asn Ser Phe Ala His Ser Leu Ser Pro Thr Leu Glu 130 135
140His Ser Ser Leu Phe Ser Gly Ser Tyr Ser Ser Leu Pro Pro Asn
Pro145 150 155 160Leu Asn Ser Arg Ala Val Glu Asp Ile Ser Ser Ser
Arg Thr Asn Pro 165 170 175Tyr Ser Tyr Ala Met Ser Thr Glu Glu Ala
Arg Phe Leu Thr Tyr His 180 185 190Met Trp Pro Leu Thr Phe Leu Ser
Pro Ser Glu Leu Ala Arg Ala Gly 195 200 205Phe Tyr Tyr Ile Gly Pro
Gly Asp Arg Val Ala Cys Phe Ala Cys Gly 210 215 220Gly Lys Leu Ser
Asn Trp Glu Pro Lys Asp Asp Ala Met Ser Glu His225 230 235 240Arg
Arg His Phe Pro Asn Cys Pro Phe Leu Glu Asn Ser Leu Glu Thr 245 250
255Leu Arg Phe Ser Ile Ser Asn Leu Ser Met Gln Thr His Ala Ala Arg
260 265 270Met Arg Thr Phe Met Tyr Trp Pro Ser Ser Val Pro Val Gln
Pro Glu 275 280 285Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Gly Arg
Asn Asp Asp Val 290 295 300Lys Cys Phe Gly Cys Asp Gly Gly Leu Arg
Cys Trp Glu Ser Gly Asp305 310 315 320Asp Pro Trp Val Glu His Ala
Lys Trp Phe Pro Arg Cys Glu Phe Leu 325 330 335Ile Arg Met Lys Gly
Gln Glu Phe Val Asp Glu Ile Gln Gly Arg Tyr 340 345 350Pro His Leu
Leu Glu Gln Leu Leu Ser Thr Ser Asp Thr Thr Gly Glu 355 360 365Glu
Asn Ala Asp Pro Pro Ile Ile His Phe Gly Pro Gly Glu Ser Ser 370 375
380Ser Glu Asp Ala Val Met Met Asn Thr Pro Val Val Lys Ser Ala
Leu385 390 395 400Glu Met Gly Phe Asn Arg Asp Leu Val Lys Gln Thr
Val Leu Ser Lys 405 410 415Ile Leu Thr Thr Gly Glu Asn Tyr Lys Thr
Val Asn Asp Ile Val Ser 420 425 430Ala Leu Leu Asn Ala Glu Asp Glu
Lys Arg Glu Glu Glu Lys Glu Lys 435 440 445Gln Ala Glu Glu Met Ala
Ser Asp Asp Leu Ser Leu Ile Arg Lys Asn 450 455 460Arg Met Ala Leu
Phe Gln Gln Leu Thr Cys Val Leu Pro Ile Leu Asp465 470 475 480Asn
Leu Leu Lys Ala Asn Val Ile Asn Lys Gln Glu His Asp Ile Ile 485 490
495Lys Gln Lys Thr Gln Ile Pro Leu Gln Ala Arg Glu Leu Ile Asp Thr
500 505 510Ile Trp Val Lys Gly Asn Ala Ala Ala Asn Ile Phe Lys Asn
Cys Leu 515 520 525Lys Glu Ile Asp Ser Thr Leu Tyr Lys Asn Leu Phe
Val Asp Lys Asn 530 535 540Met Lys Tyr Ile Pro Thr Glu Asp Val Ser
Gly Leu Ser Leu Glu Glu545 550 555 560Gln Leu Arg Arg Leu Gln Glu
Glu Arg Thr Cys Lys Val Cys Met Asp 565 570 575Lys Glu Val Ser Val
Val Phe Ile Pro Cys Gly His Leu Val Val Cys 580 585 590Gln Glu Cys
Ala Pro Ser Leu Arg Lys Cys Pro Ile Cys Arg Gly Ile 595 600 605Ile
Lys Gly Thr Val Arg Thr Phe Leu Ser 610 61592691DNAMus musculus
9attttttaaa ttgatgcatt aacattctaa acattcatct gtttttaaat agtaaaaatt
60gaactttgcc ttgaatatgt aatgattcat tataacaatt atgcatagtc tttaataatc
120tgcatatttt atgctgcttt catgtttttc ctaattaatg acttcacatg
tttaatattt 180ataatttttc tgtcatagtt tccatattta tataaaatga
atacttaaga tcagtaattc 240tgctctgttt gtttatatac tattttccat
caaaagacaa aatgggactg aggttgaggc 300tcgttgctaa agcactttcc
taaaatgcaa aaggccctat gatggatccc tagtacttat 360ttaagtgaga
gagaaacagg ctgggggtgt aggtctgtta gagcatgtgt ttggcattat
420gtgaagccca aacactaaaa aaggagaaca aacaaaagcg cagactttaa
aactcaagtg 480gtttggtaat gtacgactct actgtttaga attaaaatgt
gtcttagtta ttgtgccatt 540atttttatgt catcactgga taatatatta
gtgcttagta tcagaaatag tccttatgct 600ttgtgttttg aagttcctaa
tgcaatgttc tctttctaga aaaggtggac aagtcctatt 660ttccagagaa
gatgactttt aacagttttg aaggaactag aacttttgta cttgcagaca
720ccaataagga tgaagaattt gtagaagagt ttaatagatt aaaaacattt
gctaacttcc 780caagtagtag tcctgtttca gcatcaacat tggcgcgagc
tgggtttctt tataccggtg 840aaggagacac cgtgcaatgt ttcagttgtc
atgcggcaat agatagatgg cagtatggag 900actcagctgt tggaagacac
aggagaatat ccccaaattg cagatttatc aatggttttt 960attttgaaaa
tggtgctgca cagtctacaa atcctggtat ccaaaatggc cagtacaaat
1020ctgaaaactg tgtgggaaat agaaatcctt ttgcccctga caggccacct
gagactcatg 1080ctgattatct cttgagaact ggacaggttg tagatatttc
agacaccata tacccgagga 1140accctgccat gtgtagtgaa gaagccagat
tgaagtcatt tcagaactgg ccggactatg 1200ctcatttaac ccccagagag
ttagctagtg ctggcctcta ctacacaggg gctgatgatc 1260aagtgcaatg
cttttgttgt gggggaaaac tgaaaaattg ggaaccctgt gatcgtgcct
1320ggtcagaaca caggagacac tttcccaatt gcttttttgt tttgggccgg
aacgttaatg 1380ttcgaagtga atctggtgtg agttctgata ggaatttccc
aaattcaaca aactctccaa 1440gaaatccagc catggcagaa tatgaagcac
ggatcgttac ttttggaaca tggacatcct 1500cagttaacaa ggagcagctt
gcaagagctg gattttatgc tttaggtgaa ggcgataaag 1560tgaagtgctt
ccactgtgga ggagggctca cggattggaa gccaagtgaa gacccctggg
1620accagcatgc taagtgctac ccagggtgca aatacctatt ggatgagaag
gggcaagaat 1680atataaataa tattcattta acccatccac ttgaggaatc
tttgggaaga actgctgaaa 1740aaacaccacc gctaactaaa aaaatcgatg
ataccatctt ccagaatcct atggtgcaag 1800aagctatacg aatgggattt
agcttcaagg accttaagaa aacaatggaa gaaaaaatcc 1860aaacatccgg
gagcagctat ctatcacttg aggtcctgat tgcagatctt gtgagtgctc
1920agaaagataa tacggaggat gagtcaagtc aaacttcatt gcagaaagac
attagtactg 1980aagagcagct aaggcgccta caagaggaga agctttccaa
aatctgtatg gatagaaata 2040ttgctatcgt tttttttcct tgtggacatc
tggccacttg taaacagtgt gcagaagcag 2100ttgacaaatg tcccatgtgc
tacaccgtca ttacgttcaa ccaaaaaatt tttatgtctt 2160agtggggcac
cacatgttat gttcttcttg ctctaattga atgtgtaatg ggagcgaact
2220ttaagtaatc ctgcatttgc attccattag catcctgctg tttccaaatg
gagaccaatg 2280ctaacagcac tgtttccgtc taaacattca atttctggat
ctttcgagtt atcagctgta 2340tcatttagcc agtgttttac tcgattgaaa
ccttagacag agaagcattt tatagctttt 2400cacatgtata ttggtagtac
actgacttga tttctatatg taagtgaatt catcacctgc 2460atgtttcatg
ccttttgcat aagcttaaca aatggagtgt tctgtataag catggagatg
2520tgatggaatc
tgcccaatga ctttaattgg cttattgtaa acacggaaag aactgcccca
2580cgctgctggg aggataaaga ttgttttaga tgctcacttc tgtgttttag
gattctgccc 2640atttacttgg aatttattgg agttataatg tacttatatg
atatttccga a 269110496PRTMus musculus 10Met Thr Phe Asn Ser Phe Glu
Gly Thr Arg Thr Phe Val Leu Ala Asp 1 5 10 15Thr Asn Lys Asp Glu
Glu Phe Val Glu Glu Phe Asn Arg Leu Lys Thr 20 25 30Phe Ala Asn Phe
Pro Ser Ser Ser Pro Val Ser Ala Ser Thr Leu Ala 35 40 45Arg Ala Gly
Phe Leu Tyr Thr Gly Glu Gly Asp Thr Val Gln Cys Phe 50 55 60Ser Cys
His Ala Ala Ile Asp Arg Trp Gln Tyr Gly Asp Ser Ala Val65 70 75
80Gly Arg His Arg Arg Ile Ser Pro Asn Cys Arg Phe Ile Asn Gly Phe
85 90 95Tyr Phe Glu Asn Gly Ala Ala Gln Ser Thr Asn Pro Gly Ile Gln
Asn 100 105 110Gly Gln Tyr Lys Ser Glu Asn Cys Val Gly Asn Arg Asn
Pro Phe Ala 115 120 125Pro Asp Arg Pro Pro Glu Thr His Ala Asp Tyr
Leu Leu Arg Thr Gly 130 135 140Gln Val Val Asp Ile Ser Asp Thr Ile
Tyr Pro Arg Asn Pro Ala Met145 150 155 160Cys Ser Glu Glu Ala Arg
Leu Lys Ser Phe Gln Asn Trp Pro Asp Tyr 165 170 175Ala His Leu Thr
Pro Arg Glu Leu Ala Ser Ala Gly Leu Tyr Tyr Thr 180 185 190Gly Ala
Asp Asp Gln Val Gln Cys Phe Cys Cys Gly Gly Lys Leu Lys 195 200
205Asn Trp Glu Pro Cys Asp Arg Ala Trp Ser Glu His Arg Arg His Phe
210 215 220Pro Asn Cys Phe Phe Val Leu Gly Arg Asn Val Asn Val Arg
Ser Glu225 230 235 240Ser Gly Val Ser Ser Asp Arg Asn Phe Pro Asn
Ser Thr Asn Ser Pro 245 250 255Arg Asn Pro Ala Met Ala Glu Tyr Glu
Ala Arg Ile Val Thr Phe Gly 260 265 270Thr Trp Ile Tyr Ser Val Asn
Lys Glu Gln Leu Ala Arg Ala Gly Phe 275 280 285Tyr Ala Leu Gly Glu
Gly Asp Lys Val Lys Cys Phe His Cys Gly Gly 290 295 300Gly Leu Thr
Asp Trp Lys Pro Ser Glu Asp Pro Trp Asp Gln His Ala305 310 315
320Lys Cys Tyr Pro Gly Cys Lys Tyr Leu Leu Asp Glu Lys Gly Gln Glu
325 330 335Tyr Ile Asn Asn Ile His Leu Thr His Pro Leu Glu Glu Ser
Leu Gly 340 345 350Arg Thr Ala Glu Lys Thr Pro Pro Leu Thr Lys Lys
Ile Asp Asp Thr 355 360 365Ile Phe Gln Asn Pro Met Val Gln Glu Ala
Ile Arg Met Gly Phe Ser 370 375 380Phe Lys Asp Leu Lys Lys Thr Met
Glu Glu Lys Ile Gln Thr Ser Gly385 390 395 400Ser Ser Tyr Leu Ser
Leu Glu Val Leu Ile Ala Asp Leu Val Ser Ala 405 410 415Gln Lys Asp
Asn Thr Glu Asp Glu Ser Ser Gln Thr Ser Leu Gln Lys 420 425 430Asp
Ile Ser Thr Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Lys Leu 435 440
445Ser Lys Ile Cys Met Asp Arg Asn Ile Ala Ile Val Phe Phe Pro Cys
450 455 460Gly His Leu Ala Thr Cys Lys Gln Cys Ala Glu Ala Val Asp
Lys Cys465 470 475 480Pro Met Cys Tyr Thr Val Ile Thr Phe Asn Gln
Lys Ile Phe Met Ser 485 490 495112676DNAMus musculus 11tgggagttcc
ccggagccct ggaggaaagc accgcaggtc tgagcagccc tgagccgggc 60agggtggggg
cagtggctaa ggcctagctg gggacgattt aaaggtatcg cgccacccag
120ccacacccca caggccaggc gagggtgcca cccccggaga tcagaggtca
ttgctggcgt 180tcagagccta ggaagtgggc tgcggtatca gcctagcagt
aaaaccgacc agaagccatg 240cacaaaacta catccccaga gaaagacttg
tcccttcccc tccctgtcat ctcaccatga 300acatggttca agacagcgcc
tttctagcca agctgatgaa gagtgctgac acctttgagt 360tgaagtatga
cttttcctgt gagctgtacc gattgtccac gtattcagct tttcccaggg
420gagttcctgt gtcagaaagg agtctggctc gtgctggctt ttactacact
ggtgccaatg 480acaaggtcaa gtgcttctgc tgtggcctga tgctagacaa
ctggaaacaa ggggacagtc 540ccatggagaa gcacagaaag ttgtacccca
gctgcaactt tgtacagact ttgaatccag 600ccaacagtct ggaagctagt
cctcggcctt ctcttccttc cacggcgatg agcaccatgc 660ctttgagctt
tgcaagttct gagaatactg gctatttcag tggctcttac tcgagctttc
720cctcagaccc tgtgaacttc cgagcaaatc aagattgtcc tgctttgagc
acaagtccct 780accactttgc aatgaacaca gagaaggcca gattactcac
ctatgaaaca tggccattgt 840cttttctgtc accagcaaag ctggccaaag
caggcttcta ctacatagga cctggagata 900gagtggcctg ctttgcgtgc
gatgggaaac tgagcaactg ggaacgtaag gatgatgcta 960tgtcagagca
ccagaggcat ttccccagct gtccgttctt aaaagacttg ggtcagtctg
1020cttcgagata cactgtctct aacctgagca tgcagacaca cgcagcccgt
attagaacat 1080tctctaactg gccttctagt gcactagttc attcccagga
acttgcaagt gcgggctttt 1140attatacagg acacagtgat gatgtcaagt
gtttttgctg tgatggtggg ctgaggtgct 1200gggaatctgg agatgacccc
tgggtggaac atgccaagtg gtttccaagg tgtgagtact 1260tgctcagaat
caaaggccaa gaatttgtca gccaagttca agctggctat cctcatctac
1320ttgagcagct attatctacg tcagactccc cagaagatga gaatgcagac
gcagcaatcg 1380tgcattttgg ccctggagaa agttcggaag atgtcgtcat
gatgagcacg cctgtggtta 1440aagcagcctt ggaaatgggc ttcagtagga
gcctggtgag acagacggtt cagcggcaga 1500tcctggccac tggtgagaac
tacaggaccg tcagtgacct cgttataggc ttactcgatg 1560cagaagacga
gatgagagag gagcagatgg agcaggcggc cgaggaggag gagtcagatg
1620atctagcact aatccggaag aacaaaatgg tgcttttcca acatttgacg
tgtgtgacac 1680caatgctgta ttgcctccta agtgcaaggg ccatcactga
acaggagtgc aatgctgtga 1740aacagaaacc acacacctta caagcaagca
cactgattga tactgtgtta gcaaaaggaa 1800acactgcagc aacctcattc
agaaactccc ttcgggaaat tgaccctgcg ttatacagag 1860atatatttgt
gcaacaggac attaggagtc ttcccacaga tgacattgca gctctaccaa
1920tggaagaaca gttgcggaaa ctccaggagg aaagaatgtg taaagtgtgt
atggaccgag 1980aggtatccat cgtgttcatt ccctgtggcc atctggtcgt
gtgcaaagac tgcgctccct 2040ctctgaggaa gtgtcccatc tgtagaggga
ccatcaaggg cacagtgcgc acatttctct 2100cctgaacaag actaatggtc
catggctgca acttcagcca ggaggaagtt cactgtcact 2160cccagctcca
ttcggaactt gaggccagcc tggatagcac gagacaccgc caaacacaca
2220aatataaaca tgaaaaactt ttgtctgaag tcaagaatga atgaattact
tatataataa 2280ttttaattgg tttccttaaa agtgctattt gttcccaact
cagaaaattg ttttctgtaa 2340acatatttac atactacctg catctaaagt
attcatatat tcatatattc agatgtcatg 2400agagagggtt ttgttcttgt
tcctgaaaag cagggattgc ctgcactcct gaaattctca 2460gaaagattta
caatgttggc atttatggtt cagaaactag aatcttctcc cgttgcttta
2520agaaccggga gcacagatgt ccatgtgttt tatgtataga aattcctgtt
atttattgga 2580tgacatttta gggatatgaa atttttataa agaatttgtg
agaaaaagtt aataaagcaa 2640cataattacc tctttttttt taaagaaaaa aaaaaa
267612600PRTMus musculus 12Met Val Gln Asp Ser Ala Phe Leu Ala Lys
Leu Met Lys Ser Ala Asp 1 5 10 15Thr Phe Glu Leu Lys Tyr Asp Phe
Ser Cys Glu Leu Tyr Arg Leu Ser 20 25 30Thr Tyr Ser Ala Phe Pro Arg
Gly Val Pro Val Ser Glu Arg Ser Leu 35 40 45Ala Arg Ala Gly Phe Tyr
Tyr Thr Gly Ala Asn Asp Lys Val Lys Cys 50 55 60Phe Cys Cys Gly Leu
Met Leu Asp Asn Trp Lys Gln Gly Asp Ser Pro65 70 75 80Met Glu Lys
His Arg Lys Leu Tyr Pro Ser Cys Asn Phe Val Gln Thr 85 90 95Leu Asn
Pro Ala Asn Ser Leu Glu Ala Ser Pro Arg Pro Ser Leu Pro 100 105
110Ser Thr Ala Met Ser Thr Met Pro Leu Ser Phe Ala Ser Ser Glu Asn
115 120 125Thr Gly Tyr Phe Ser Gly Ser Tyr Ser Ser Phe Pro Ser Asp
Pro Val 130 135 140Asn Phe Arg Ala Asn Gln Asp Cys Pro Ala Leu Ser
Thr Ser Pro Tyr145 150 155 160His Phe Ala Met Asn Thr Glu Lys Ala
Arg Leu Leu Thr Tyr Glu Thr 165 170 175Trp Pro Leu Ser Phe Leu Ser
Pro Ala Lys Leu Ala Lys Ala Gly Phe 180 185 190Tyr Tyr Ile Gly Pro
Gly Asp Arg Val Ala Cys Phe Ala Cys Asp Gly 195 200 205Lys Leu Ser
Asn Trp Glu Arg Lys Asp Asp Ala Met Ser Glu His Gln 210 215 220Arg
His Phe Pro Ser Cys Pro Phe Leu Lys Asp Leu Gly Gln Ser Ala225 230
235 240Ser Arg Tyr Thr Val Ser Asn Leu Ser Met Gln Thr His Ala Ala
Arg 245 250 255Ile Arg Thr Phe Ser Asn Trp Pro Ser Ser Ala Leu Val
His Ser Gln 260 265 270Glu Leu Ala Ser Ala Gly Phe Tyr Tyr Thr Gly
His Ser Asp Asp Val 275 280 285Lys Cys Phe Cys Cys Asp Gly Gly Leu
Arg Cys Trp Glu Ser Gly Asp 290 295 300Asp Pro Trp Val Glu His Ala
Lys Trp Phe Pro Arg Cys Glu Tyr Leu305 310 315 320Leu Arg Ile Lys
Gly Gln Glu Phe Val Ser Gln Val Gln Ala Gly Tyr 325 330 335Pro His
Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp Ser Pro Glu Asp 340 345
350Glu Asn Ala Asp Ala Ala Ile Val His Phe Gly Pro Gly Glu Ser Ser
355 360 365Glu Asp Val Val Met Met Ser Thr Pro Val Val Lys Ala Ala
Leu Glu 370 375 380Met Gly Phe Ser Arg Ser Leu Val Arg Gln Thr Val
Gln Arg Gln Ile385 390 395 400Leu Ala Thr Gly Glu Asn Tyr Arg Thr
Val Ser Asp Leu Val Ile Gly 405 410 415Leu Leu Asp Ala Glu Asp Glu
Met Arg Glu Glu Gln Met Glu Gln Ala 420 425 430Ala Glu Glu Glu Glu
Ser Asp Asp Leu Ala Leu Ile Arg Lys Asn Lys 435 440 445Met Val Leu
Phe Gln His Leu Thr Cys Val Thr Pro Met Leu Tyr Cys 450 455 460Leu
Leu Ser Ala Arg Ala Ile Thr Glu Gln Glu Cys Asn Ala Val Lys465 470
475 480Gln Lys Pro His Thr Leu Gln Ala Ser Thr Leu Ile Asp Thr Val
Leu 485 490 495Ala Lys Gly Asn Thr Ala Ala Thr Ser Phe Arg Asn Ser
Leu Arg Glu 500 505 510Ile Asp Pro Ala Leu Tyr Arg Asp Ile Phe Val
Gln Gln Asp Ile Arg 515 520 525Ser Leu Pro Thr Asp Asp Ile Ala Ala
Leu Pro Met Glu Glu Gln Leu 530 535 540Arg Lys Leu Gln Glu Glu Arg
Met Cys Lys Val Cys Met Asp Arg Glu545 550 555 560Val Ser Ile Val
Phe Ile Pro Cys Gly His Leu Val Val Cys Lys Asp 565 570 575Cys Ala
Pro Ser Leu Arg Lys Cys Pro Ile Cys Arg Gly Thr Ile Lys 580 585
590Gly Thr Val Arg Thr Phe Leu Ser 595 600133151DNAMus musculus
13agttatataa aatacgaagt tttcaaaaag aaggctagtg caacagaaaa gctttgctaa
60aacagattct tagttatttg aggtaacaaa agaaagccat gtcttgaatt gattcgttct
120taattataac agacttatag tggaaagggc cttaaacaca ggcggacttt
ataaaatgca 180gtcttaggtt tatgtgcaaa atactgtctg ttgaccagat
gtattcacat gatatataca 240gagtcaaggt ggtgatatag aagatttaac
agtgagggag ttaacagtct gtgctttaag 300cgcagttcct ttacagtgaa
tactgtagtc ttaatagacc tgagctgact gctgcagttg 360atgtaaccca
ctttagagaa tactgtatga catcttctct aaggaaaacc agctgcagac
420ttcactcagt tcctttcatt tcataggaaa aggagtagtt cagatgtcat
gtttaagtcc 480ttataaggga aaagagcctg aatatatgcc ctagtaccta
ggcttcataa ctagtaataa 540gaagttagtt atgggtaaat agatctcagg
ttacccagaa gagttcatgt gacccccaaa 600gagtcctaac tagtgtcttg
gcaagtgaga cagatttgtc ctgtgagggt gtcaattcac 660cagtccaagc
agaagacaat gaatctatcc agtcaggtgt ctgtggtgga gatctagtgt
720ccaagtggtg agaaacttca tctggaagtt taagcggtca gaaatactat
tactactcat 780ggacaaaact gtctcccaga gactcggcca aggtacctta
caccaaaaac ttaaacgtat 840aatggagaag agcacaatct tgtcaaattg
gacaaaggag agcgaagaaa aaatgaagtt 900tgacttttcg tgtgaactct
accgaatgtc tacatattca gcttttccca ggggagttcc 960tgtctcagag
aggagtctgg ctcgtgctgg cttttattat acaggtgtga atgacaaagt
1020caagtgcttc tgctgtggcc tgatgttgga taactggaaa caaggggaca
gtcctgttga 1080aaagcacaga cagttctatc ccagctgcag ctttgtacag
actctgcttt cagccagtct 1140gcagtctcca tctaagaata tgtctcctgt
gaaaagtaga tttgcacatt cgtcacctct 1200ggaacgaggt ggcattcact
ccaacctgtg ctctagccct cttaattcta gagcagtgga 1260agacttctca
tcaaggatgg atccctgcag ctatgccatg agtacagaag aggccagatt
1320tcttacttac agtatgtggc ctttaagttt tctgtcacca gcagagctgg
ccagagctgg 1380cttctattac atagggcctg gagacagggt ggcctgtttt
gcctgtggtg ggaaactgag 1440caactgggaa ccaaaggatg atgctatgtc
agagcaccgc agacattttc cccactgtcc 1500atttctggaa aatacttcag
aaacacagag gtttagtata tcaaatctaa gtatgcagac 1560acactctgct
cgattgagga catttctgta ctggccacct agtgttcctg ttcagcccga
1620gcagcttgca agtgctggat tctattacgt ggatcgcaat gatgatgtca
agtgcttttg 1680ttgtgatggt ggcttgagat gttgggaacc tggagatgac
ccctggatag aacacgccaa 1740atggtttcca aggtgtgagt tcttgatacg
gatgaagggt caggagtttg ttgatgagat 1800tcaagctaga tatcctcatc
ttcttgagca gctgttgtcc acttcagaca ccccaggaga 1860agaaaatgct
gaccctacag agacagtggt gcattttggc cctggagaaa gttcgaaaga
1920tgtcgtcatg atgagcacgc ctgtggttaa agcagccttg gaaatgggct
tcagtaggag 1980cctggtgaga cagacggttc agcggcagat cctggccact
ggtgagaact acaggaccgt 2040caatgatatt gtctcagtac ttttgaatgc
tgaagatgag agaagagaag aggagaagga 2100aagacagact gaagagatgg
catcaggtga cttatcactg attcggaaga atagaatggc 2160cctctttcaa
cagttgacac atgtccttcc tatcctggat aatcttcttg aggccagtgt
2220aattacaaaa caggaacatg atattattag acagaaaaca cagataccct
tacaagcaag 2280agagcttatt gacaccgttt tagtcaaggg aaatgctgca
gccaacatct tcaaaaactc 2340tctgaaggaa attgactcca cgttatatga
aaacttattt gtggaaaaga atatgaagta 2400tattccaaca gaagacgttt
caggcttgtc attggaagag cagttgcgga gattacaaga 2460agaacgaact
tgcaaagtgt gtatggacag agaggtttct attgtgttca ttccgtgtgg
2520tcatctagta gtctgccagg aatgtgcccc ttctctaagg aagtgcccca
tctgcagggg 2580gacaatcaag gggactgtgc gcacatttct ctcatgagtg
aagaatggtc tgaaagtatt 2640gttggacatc agaagctgtc agaacaaaga
atgaactact gatttcagct cttcagcagg 2700acattctact ctctttcaag
attagtaatc ttgctttatg aagggtagca ttgtatattt 2760aagcttagtc
tgttgcaagg gaaggtctat gctgttgagc tacaggactg tgtctgttcc
2820agagcaggag ttgggatgct tgctgtatgt ccttcaggac ttcttggatt
tggaatttgt 2880gaaagctttg gattcaggtg atgtggagct cagaaatcct
gaaaccagtg gctctggtac 2940tcagtagtta gggtaccctg tgcttcttgg
tgcttttcct ttctggaaaa taaggatttt 3000tctgctactg gtaaatattt
tctgtttgtg agaaatatat taaagtgttt cttttaaagg 3060cgtgcatcat
tgtagtgtgt gcagggatgt atgcaggcaa aacactgtgt atataataaa
3120taaatctttt taaaaagtgt aaaaaaaaaa a 315114612PRTMus musculus
14Met Asp Lys Thr Val Ser Gln Arg Leu Gly Gln Gly Thr Leu His Gln 1
5 10 15Lys Leu Lys Arg Ile Met Glu Lys Ser Thr Ile Leu Ser Asn Trp
Thr 20 25 30Lys Glu Ser Glu Glu Lys Met Lys Phe Asp Phe Ser Cys Glu
Leu Tyr 35 40 45Arg Met Ser Thr Tyr Ser Ala Phe Pro Arg Gly Val Pro
Val Ser Glu 50 55 60Arg Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly
Val Asn Asp Lys65 70 75 80Val Lys Cys Phe Cys Cys Gly Leu Met Leu
Asp Asn Trp Lys Gln Gly 85 90 95Asp Ser Pro Val Glu Lys His Arg Gln
Phe Tyr Pro Ser Cys Ser Phe 100 105 110Val Gln Thr Leu Leu Ser Ala
Ser Leu Gln Ser Pro Ser Lys Asn Met 115 120 125Ser Pro Val Lys Ser
Arg Phe Ala His Ser Ser Pro Leu Glu Arg Gly 130 135 140Gly Ile His
Ser Asn Leu Cys Ser Ser Pro Leu Asn Ser Arg Ala Val145 150 155
160Glu Asp Phe Ser Ser Arg Met Asp Pro Cys Ser Tyr Ala Met Ser Thr
165 170 175Glu Glu Ala Arg Phe Leu Thr Tyr Ser Met Trp Pro Leu Ser
Phe Leu 180 185 190Ser Pro Ala Glu Leu Ala Arg Ala Gly Phe Tyr Tyr
Ile Gly Pro Gly 195 200 205Asp Arg Val Ala Cys Phe Ala Cys Gly Gly
Lys Leu Ser Asn Trp Glu 210 215 220Pro Lys Asp Asp Ala Met Ser Glu
His Arg Arg His Phe Pro His Cys225 230 235 240Pro Phe Leu Glu Asn
Thr Ser Glu Thr Gln Arg Phe Ser Ile Ser Asn 245 250 255Leu Ser Met
Gln Thr His Ser Ala Arg Leu Arg Thr Phe Leu Tyr Trp 260 265 270Pro
Pro Ser Val Pro Val Gln Pro Glu Gln Leu Ala Ser Ala Gly Phe 275 280
285Tyr Tyr Val Asp Arg Asn Asp Asp Val Lys Cys Phe Cys Cys Asp Gly
290 295 300Gly Leu Arg Cys Trp Glu Pro Gly Asp Asp Pro Trp Ile Glu
His Ala305 310 315 320Lys Trp Phe Pro Arg Cys Glu Phe Leu Ile Arg
Met Lys Gly Gln Glu 325 330 335Phe Val Asp Glu Ile Gln Ala Arg Tyr
Pro His Leu Leu Glu Gln Leu 340 345 350Leu Ser Thr Ser Asp Thr Pro
Gly Glu Glu Asn Ala Asp Pro Thr Glu 355 360 365Thr
Val Val His Phe Gly Pro Gly Glu Ser Ser Lys Asp Val Val Met 370 375
380Met Ser Thr Pro Val Val Lys Ala Ala Leu Glu Met Gly Phe Ser
Arg385 390 395 400Ser Leu Val Arg Gln Thr Val Gln Arg Gln Ile Leu
Ala Thr Gly Glu 405 410 415Asn Tyr Arg Thr Val Asn Asp Ile Val Ser
Val Leu Leu Asn Ala Glu 420 425 430Asp Glu Arg Arg Glu Glu Glu Lys
Glu Arg Gln Thr Glu Glu Met Ala 435 440 445Ser Gly Asp Leu Ser Leu
Ile Arg Lys Asn Arg Met Ala Leu Phe Gln 450 455 460Gln Leu Thr His
Val Leu Pro Ile Leu Asp Asn Leu Leu Glu Ala Ser465 470 475 480Val
Ile Thr Lys Gln Glu His Asp Ile Ile Arg Gln Lys Thr Gln Ile 485 490
495Pro Leu Gln Ala Arg Glu Leu Ile Asp Thr Val Leu Val Lys Gly Asn
500 505 510Ala Ala Ala Asn Ile Phe Lys Asn Ser Leu Lys Glu Ile Asp
Ser Thr 515 520 525Leu Tyr Glu Asn Leu Phe Val Glu Lys Asn Met Lys
Tyr Ile Pro Thr 530 535 540Glu Asp Val Ser Gly Leu Ser Leu Glu Glu
Gln Leu Arg Arg Leu Gln545 550 555 560Glu Glu Arg Thr Cys Lys Val
Cys Met Asp Arg Glu Val Ser Ile Val 565 570 575Phe Ile Pro Cys Gly
His Leu Val Val Cys Gln Glu Cys Ala Pro Ser 580 585 590Leu Arg Lys
Cys Pro Ile Cys Arg Gly Thr Ile Lys Gly Thr Val Arg 595 600 605Thr
Phe Leu Ser 6101521DNAArtificial SequenceBased on Homo sapiens
sequence 15agtgcgggtt tttattatgt g 211625DNAArtificial
SequenceBased on Homo sapiens sequence 16agatgaccac aaggaataaa
cacta 251711PRTArtificial SequenceBased on Homo sapiens sequence
17Met Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10
* * * * *